Internship report: experience in Bluepharma's pharmacovigilance sector by Jorge, Pedro André Alves
 Universidade de Aveiro  
2014 
Secção Autónoma de Ciências da 
Saúde 
Pedro André  
Alves Jorge 
 
Internship Report: Experience in Bluepharma’s 
pharmacovigilance sector 
 
 
 
   
  
    
 
 
Universidade de 
Aveiro  
2014 
Secção Autónoma de Ciências da Saúde 
Pedro André  
Alves Jorge 
 
Internship Report: Experience in Bluepharma’s 
pharmacovigilance sector 
 
 Relatório de estágio apresentado à Universidade de Aveiro para 
para cumprimento dos requisitos necessários à obtenção do grau 
de Mestre em Biomedicina Farmacêutica, realizado sob a 
orientação científica do Professor Doutor Sérgio Paulo Magalhães 
Simões, Vice-Presidente da Bluepharma – Indústria 
Farmacêutica, S.A. e Professor Auxiliar com agregação da 
Faculdade de Farmácia da Universidade de Coimbra e da 
Professora Doutora Alexandra Isabel Cardador de Queirós, 
Professora Coordenadora Sem Agregação da Escola Superior de 
Saúde da Saúde da Universidade de Aveiro. 
 
 
 
 
  
    
 
  
 
 
 
 
 
 
o júri   
 
presidente Professor Doutor Nelson Fernando Pacheco da Rocha 
Professor Catedrático, Universidade de Aveiro 
  
arguente principal Doutor Bruno Miguel Alves Fernandes do Gago  
Professor Auxiliar Convidado, Universidade de Aveiro 
  
Orientador Professora Doutora Alexandra Isabel Cardador de Queirós 
Professora Coordenadora S/ Agregação, Universidade de Aveiro 
  
  
  
  
  
  
  
  
 
 
 
  
  
    
 
  
 
  
 
agradecimentos 
 
Para o sucesso alcançado durante este mestrado, eu tenho que 
agradecer às seguintes pessoas: 
Ao Prof. Dr. Sérgio Simões por me ter permitido pertencer à equipa 
Bluepharma, o que possibilitou a realização deste estágio. 
À Dra. Diná Campos, que acreditou que eu seria a pessoa certa para 
trabalhar em farmacovigilância, agradeço todo o apoio e conhecimentos 
transmitidos ao longo de todo este estágio. 
Ao Prof. Dr. Luís Almeida e ao Prof. Dr. Bruno Gago agradeço por toda 
a orientação e conhecimentos transmitidos ao longo de todo o mestrado 
e pela organização do Mestrado em Biomedicina Farmacêutica. 
À Profª. Dra. Alexandra Queirós pela sua disponibilidade para rever 
este relatório e pelos seus conselhos para a sua melhoria. 
Agradeço a toda a equipa dos Assuntos Regulamentares da 
Bluepharma por me ter recebido no seu departamento. Agradeço 
também por todos os conhecimentos e conselhos transmitidos ao longo 
deste estágio. 
Por fim, agradeço a toda a família, amigos e colegas que me 
acompanharam ao longo de todo este percurso, desde que entrei pela 
primeira vez na Universidade de Aveiro até este momento. 
 
  
    
 
 
Universidade de Aveiro  
2014 
Secção Autónoma de Ciências da  
Saúde 
 
  
palavras-chave 
 
Universidade de Aveiro; Biomedicina Farmacêutica; Bluepharma; Medicamento; 
Farmacovigilância; Segurança; Regulamentar; 
resumo 
 
 
O presente relatório descreve um estágio curricular no âmbito do 
mestrado em Biomedicina Farmacêutica da Universidade de Aveiro 
realizado ao longo de dez meses no sector de farmacovigilância da 
empresa farmacêutica Bluepharma – Indústria Farmacêutica, S.A. 
Os profissionais da Biomedicina Farmacêutica, no âmbito da sua 
formação, desenvolvem conhecimentos de conceitos teóricos e 
processuais associados à farmacovigilância (ciência relacionada com a 
segurança de medicamentos). Os objetivos deste estágio previam a 
colocação em prática desses conhecimentos, bem como a aquisição e 
aprofundamento de conhecimentos relacionados com as matérias de 
farmacovigilância e segurança de medicamentos de uso humano em 
contexto profissional. 
O relatório encontra-se dividido em quatro partes. Numa primeira parte 
são descritos os objetivos deste estágio e o estado-de-arte da 
farmacovigilância. Uma descrição das atividades envolvidas neste 
estágio é apresentada na segunda parte, seguida da sua discussão na 
terceira parte. Por fim, é apresentada uma conclusão onde são 
discutidos os principais conhecimentos adquiridos e qual importância da 
experiência académica para complemento da formação. 
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The present report is intended to describe a ten-month internship for the 
master degree in Pharmaceutical Medicine in University of Aveiro 
performed in the pharmacovigilance sector of the pharmaceutical 
company Bluepharma – Indústria Farmacêutica, S.A. 
Pharmaceutical Medicine professionals, based on their background, 
have knowledge about theoretical and procedural concepts related to 
pharmacovigilance (the science responsible for the study of safety of 
medicinal products). The objectives of this internship forecasted the 
application of this knowledge, as well the acquisition and improvement of 
knowledge related to the pharmacovigilance and medicinal products’ 
safety in a professional setting. 
This report is divided in four sections. In section one a description of 
internship objectives and current state-of-art of pharmacovigilance is 
presented. The activities performed during this internship are described 
on section two, followed by their discussion on section three. Finally, 
section four presents a conclusion analysing the main skills and 
knowledge gained during this internship and their relevance for 
complementing academic experience. 
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1 INTRODUCTION  
 
In order to accomplish my curricular plan for Master degree at University of 
Aveiro’s Trainning Program in Pharmaceutical Medicine, I performed a ten-
month internship at Bluepharma’s Regulatory Affairs & Pharmacovigilance 
Department, more precisely on its Pharmacovigilance sector. The present 
report is intended to describe this experience. 
 
1.1 Objectives 
 
My ten-month internship at Bluepharma’s Regulatory Affairs & 
Pharmacovigilance department had three main objectives (also subdivided): 
 
1. To obtain and develop skills related to the pharmacovigilance field: 
o To be familiarized with the most relevant pharmacovigilance 
activities in European Economic Area (EEA); 
o To understand EEA pharmacovigilance requirements; 
o To understand the role of pharmacovigilance in the maintenance 
of medicines marketing authorizations (MA). 
 
2. To obtain and develop skills related to regulatory affairs: 
o To get knowledge about EEA pharmaceutical legislation 
framework; 
o To obtain a deeper understanding on the applicability of the 
European and Portuguese pharmaceutical legislation framework. 
 
3. To acquire experience within the regulatory affairs field inside a 
pharmaceutical company: 
o To be integrated within company’s projects; 
o To observe how communication flows throughout the various 
sectors within a pharmaceutical company; 
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o To develop critical judgment about established (or to be 
established) procedures; 
o To observe the assessment of the compliance between what is 
written (e.g. Standard Operating Procedures) and what is 
performed; 
o To observe how communication with the authorities is established 
and maintained. 
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1.2 Report Structure 
 
This report is divided in four sections. In this section, Introduction, I described 
my objectives for this curricular internship, current state-of–the-art of drug 
development and pharmacovigilance, and main challenges faced by 
pharmaceutical companies in EEA due to the new pharmacovigilance 
legislation. Also, in this section I made a short description of the host company. 
Internal training sessions and working experience were described in section 
two. The accomplishment of proposed objectives was discussed on section 
three. In the last section, I presented the main conclusions and outcomes of this 
internship and related it to my academic background. 
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1.3 State of the Art 
 
Pharmaceutical Medicine is a medical science that can and should be involved 
in the various stages of medicinal products lifecycle. Since the initial stages, 
related to product’s discovery and development, throughout its licensing and 
post-marketing stages, Pharmaceutical Medicine professionals are involved in a 
variety of activities with the final goal to provide safe and effective medicines to 
the public (1). In this section I will describe the traditional life-cycle of a 
medicinal product and make a succinct state-of-the art of pharmacovigilance, 
where most of my internship activities were focused.  
 
1.3.1 Product Life-Cycle 
A medicine is a living and dynamic entity which life-cycle begins when a 
company decides to develop it and lasts until the moment it is withdrawn from 
the market. The cycle starts with the development of the product, which can 
encompass pharmaceutical, non-clinical and clinical development depending on 
the type of product, followed by authorities’ approval. After the product launch 
into the market, where it finally become available to the patients, a phase 
characterized by an increase in sales generally occurs, motivated not only for 
the novelty factor that usually is linked to the marketing of a New Chemical 
Entity, but also for the extensive promotion plan that any given company will put 
in place in the very first years of marketing. It then follows a maturity phase, 
where the product sales stabilize. The final phase is designated by Decline 
phase and it is characterized by a significant decrease in product’s sales (see 
Figure 1) (2).  
In this section, details are provided regarding the following stages of a medicinal 
product life-cycle: 
 Product Development; 
 Marketing Authorization;  
 Decline phase. 
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Figure 1 – Medicinal product life-cycle (image taken from: http://www.soopertutorials.com/wp-
content/uploads/2009/03/market-stages-thumb.gif) 
 
Product Development 
A medicinal product, as any other product intended to be marketed, starts its 
life-cycle, after it is discover, with the development phase. This is a long and 
costly process. It can pass more than ten years since the beginning of pre-
clinical studies until the medicine finally receives the marketing approval and the 
development costs may easily arise to the millions of dollars, sometimes even 
billions. Attrition rates are also high, with only one over tens of thousands 
compounds found during screening phase reaching the market (see Figure 2).  
(2). 
As shown in Figure 2, the pre-clinical phase comprises the studies used to 
identify the potential lead compounds for clinical studies. During this phase, 
through in vitro (e.g target identification, target validation…) and in vivo studies 
(e.g toxicology studies, safety studies…) the potential for a chemical entity to 
interact with an identified biological target and its safety are evaluated (2, 3).  
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Figure 2 – Phases involved in drug discovery process (image taken from PhRMA Industry Profile 2012) 
 
Within the traditional model, the clinical development of a new medicine 
generally consists in four phases (4). Phases I to III comprises a battery of 
studies in humans needed for approval. Phase IV includes a number of studies 
that are normally undertaken after MA. The main features of each phase are 
presented on Table 1 (1, 4): 
 
Table 1 – Clinical development phases (1, 4) 
Type of Study Main Features 
Phase I 
(or Human Pharmacology 
studies) 
 First in human trials 
 Evaluation of medicine’s tolerability; 
 Describe main pharmacokinetics and pharmacodynamics 
characteristics; 
 Determine drug interactions; 
 Estimate activity; 
 Healthy volunteer; 
 30 to 50 subjects; 
Phase II 
(or Therapeutic Exploratory 
studies) 
 First studies on the target population; 
 Dose estimation; 
 Scientific basis for trial design of larger clinical trials; 
 250 to 500 subjects; 
Phase III  Determine drug’s efficacy; 
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Type of Study Main Features 
(or Therapeutic 
Confirmatory studies) 
 Determine the safety profile; 
 Dose-response relationship 
 Scientific basis for regulatory evaluation during marketing 
authorization application; 
 Over one thousand patients exposed; 
Phase IV 
(or Therapeutic Use 
studies) 
 Improvement on the benefit-risk profile of the medicine 
(general and/or special populations); 
 Evaluation of the medicine under marketing conditions; 
 Identification of rare and very rare ADRs; 
 Optimize dosing recommendations; 
 Over ten thousands patients exposed; 
 
However, due to their relevance for product development, some studies usually 
considered to be part of a specific phase can be conducted in other distinct 
phases (see Figure 3). 
 
 
Figure 3 – Relationship between type of study and phase of develoment (4) 
 
This model is the usually followed for the development of new medicines. When 
a company intends to obtain a MA for a generic medicine clinical studies must 
be underwent also. However, the clinical program required is considerably 
streamlined.  
Since in this phase the efficacy and the safety profiles of the reference 
medicinal product are already well studied, there is no longer the need for a 
company to develop an extensive clinical plan. As referred on article 10(a) of 
Directive 2001/83/EC, generic medicinal products must prove that they are 
bioequivalent to their reference medicinal products. In order to accomplish this 
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purpose, companies shall conduct Bioequivalence/Bioavailability (BA/BE) 
studies (5). 
A BA/BE study is intended to demonstrate that a given investigational medicinal 
product is pharmaceutically equivalent to a medicinal product already in the 
market (referred as Reference medicinal product). Two products are considered 
pharmaceutically equivalents if bioavailability parameters (such as Peak 
Concentration or Area Under the Curve) are within a certain range (normally 
between 80% to 125%). If bioequivalence is proved, that will mean that both 
products have the same safety/efficacy profile and risk-benefit ratio (6). 
 
Although in my internship the thematic of innovative drugs development and its 
lifecycle has been approached for several times, the scope of my activities was 
always focused on the generic medicinal products. I had the opportunity to be 
involved in a wide range of pharmacovigilance activities related to the approved 
generic medicinal products and with some safety activities specifically related to 
the development of generic medicinal products. 
 
Marketing Authorization  
After successfully complete the investigational/development plan for a medicine, 
the next logical step for a company is its placement on the market, either on its 
own name or through license agreements. In order to have a product on the 
market under its name, any given company has to apply for a marketing 
authorization – Marketing Authorization Application (MAA). MAA process 
involves the submission of a dossier containing all the relevant administrative 
data/prescribing information and required technical/scientific data: 
 Pharmaceutical data 
 Non-clinical data 
 Clinical data 
 
On International Conference on Harmonisation (ICH) regions (European Union 
(EU), United States of America (USA) and Japan), as well as on other countries 
that recognize ICH standards, the structure of the above mentioned dossier is 
well established and is known as Common Technical Document (CTD). CTD 
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represents a harmonized way to submit the information related to a medicinal 
product in the three ICH regions. This dossier should contain the most up-to-
date technical and scientific information related to the medicine. 
As presented on Figure 4, CTD’s structure has five individual modules on its 
structure (7): 
 Module 1: “Administrative Information and Prescribing Information” 
– this module should contain all regional-specific documentation 
necessary for the marketing authorization, such as application forms and 
labels. Due to its regional nature, this is the only CTD module that 
contains distinct information in all three regions; 
 Module 2: “Common Technical Document Summaries” – this should 
be an introductory module where the medicinal product is presented, and 
an overview of its technical and scientific features is made; 
 Module 3: “Quality” – this is the section dedicated to description of 
product’s technical features, such as manufacturing process, stabilities, 
specifications and quality controls; 
 Module 4: “Nonclinical Study Reports” – in this section, a compilation 
of all non-clinical studies relevant to the safety and efficacy of the 
medicinal product is made; 
 Module 5: “Clinical Study Reports” – this module contains the 
information related to the studies made on humans; 
As already referred in this section, besides from BA/BE studies, a MAA for a 
generics do not require the submission of non-clinical and clinical study results. 
In practice this will lead to the submission of simplified CTDs, where module 4 
and some sections of module 5 are suppressed (8). 
After a MAA had been approved, the medicine can finally be marketed. 
However, the Marketing Authorization Holder (MAH) still has to comply with 
several requirements in order to maintain the MA. Those requirements are 
intended to constantly evaluate and maintain the safety and efficacy balance 
during daily practice. A generic medicine must keep up-to-date the scientific 
information with the reference medicine (5) and with the applicable technical-
scientific and legal requirements. 
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During my internship I had the opportunity to contribute to the elaboration of the 
following relevant documents for more than one CTD, within the scope of EU 
MAA: 
 1.3.1 – Proposed prescribing information (Summary of Product 
Characteristics (SmPC) and Package Leaflet) 
 1.8.1 – Update documentation related to PhSMF 
 1.8.2 – Risk Management Plans 
 2.5.6 – Addendum to clinical overview (during renewals) 
 
 
Figure 4 – CTD structure (image taken from http://www.ich.org/products/ctd.html) 
The MA, except in special cases determined by the authorities, has to be 
renewed after the first five years. During the submission of the renewal, the 
MAH should provide an overview of the first five years on the market. After the 
renewal approval the MA will have unlimited validity (5).  
In what specifically concerns to the safety, the renewal applications requires a 
critical assessment of product’s safety profile in the five-year period. Therefore, 
an addendum of the clinical overview (Sub-module 2.5) should be prepared and 
submitted as part of the renewal application. During renewal procedures, 
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reference information of generic medicines should be updated to in line with 
reference product’s information. 
During my internship, I had the opportunity to collaborate in the assessment of 
approved SmPC and Package Leaflets and to be involved on the preparation of 
addendums of clinical overviews. 
 
Decline phase 
Decline phase refers to the phase when products sales decreases after 
reaching maturity (this is a phase when sales are stabilized). For innovative 
products this generally starts to happen when its market exclusivity period ends 
and/or patent are off, which ends with any protective measures against the 
generic medicinal products. As stated in Article 10 of Directive 2001/83/EC, in 
the EEA generic medicines can only be marketed ten years after the innovative 
product approval (marketing exclusivity period).  
MAAs for generic medicinal products can start to be submitted eight years after 
the first MA for the innovative product in the EEA (data protection period), 
however those products can only be placed on the market ten years after the 
innovative product’s MA. 
 
1.3.2 Pharmacovigilance 
Pharmacovigilance concerns to the science responsible for studying safety 
issues related to the medicines use (9). Etiologically, pharmacovigilance is the 
combination of the Greek word pharmakon (meaning drug) with the Latin word 
vigilare (meaning keep watch). The first appearance of this term on scientific 
literature occurred in 1974 by Dunlop D (10), however the roots back to 1960s, 
decade with the scandal related to thalidomide’s use by pregnant women. 
Pharmacovigilance is defined as the “science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any 
other medicine-related problem” (11). It has the objective to provide to health 
care professionals and general public the most recent data and conclusions 
regarding the safe use of medicines. 
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History 
As referred previously, pharmacovigilance has its roots in the 1960s following 
the thalidomide’s scandal. After this episode it became clear that the legislation 
at that time did not provided adequate protection to patients against medicines’ 
harmful effects. It was necessary to introduce new safety and efficacy criteria 
for the approval of new medicinal products (9). 
Concomitantly to the need of establishing new criteria for marketing approval, it 
was also identified the need for MAHs and authorities to implement effective 
post-marketing surveillance system aiming the detection as early as possible 
the occurrence of Adverse Drug Reactions (ADR) related to the medicine (9). 
 
During the sixteenth World Health Organization (WHO) general assembly, in 
1963, it was defined that a surveillance system for ADRs in a global level should 
be implemented.  Currently, this system is based in the Swedish Uppsala 
Monitoring Centre and WHO is responsible for its maintenance. Some of the 
most important moments that lead to its creation were the following ones (12): 
 In 1968, the WHO Pilot Research Project for International Drug 
Monitoring was created; 
 In 1971, the WHO International Drug Monitoring Programme was 
created; 
 In 1978, Uppsala Monitoring Centre was established as base for WHO 
surveillance system; 
 VigiBase creation in mid 1990s. 
 
Another important moment in pharmacovigilance history is the creation in 1949 
of the Council for International Organizations of Medical Sciences (CIOMS). 
This entity had the objective to create, facilitate and promote international 
activities in the field of biomedical sciences. Medicines’ safety was one of the 
topics for which CIOMS published guidance documents. These guidance 
documents describe in detail how MAHs should perform their activities, either in 
pre-authorization either in post-authorization phases (13, 14). 
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In Europe notable changes on pharmacovigilance field were observed since 
2001. Following the publication of the “Directive 2001/83/EC of the European 
Parliament and of the Council of 6 November 2001 on the Community Code 
Relating to Medicinal Products for Human Use” (hereafter referred Directive 
2001/83/EC) member states should have implemented pharmacovigilance 
systems in order to collect safety information related to marketed medicines and 
to evaluate such information in a scientifically way, as stated on Article 102 (5). 
Within this directive MAHs were obligated to have in their pharmacovigilance 
systems a Qualified Person responsible for Pharmacovigilance (EU-QPPV). As 
present on Article 107, EU-QPPV is responsible for (5): 
 Creation and maintenance of the pharmacovigilance structure and 
system of a company; 
 Supervising all pharmacovigilance collaborators of Bluepharma. The 
QPPV is responsible for assign specific task to the pharmacovigilance 
collaborators and for their appropriate training; 
 Pharmacovigilance System Master File maintenance; 
 Having an overview of medicinal product safety profiles and any 
emerging safety concerns; 
 Having awareness of risk minimisation measures; 
 Ensuring that all suspected ADRs reported to MAH are recorded and 
analysed scientifically; 
 Preparation of reports to be sent to authorities;  
 Ensuring that any request of the authorities related to the safety of the 
medicine is promptly satisfied; 
 Provision of any other information relevant to the benefit-risk evaluation 
of a medicine; 
 Supervising all pharmacovigilance collaborators of Bluepharma. The 
QPPV is responsible for assign specific task to the pharmacovigilance 
collaborators and for their appropriate training; 
Another important reform introduced by the Directive 2001/83/EC was the 
creation of an European system allowing a faster exchange of 
pharmacovigilance data between European competent authorities. As present 
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on Article 105, this system is known as Eudravigilance and European Medicines 
Agency (EMA) is responsible for its development and maintenance (5). 
In 2004, aiming to improve and harmonize European procedures applied in the 
pharmacovigilance activities, European Commission (EC) approved the 
Regulation No. 726/2004 of 31 March 2004. This regulation established the 
roles and responsibilities for the several stakeholders involved in 
pharmacovigilance activities within EU. 
 
A new revolution in European pharmacovigilance legislation occurred between 
2010 and 2012. In this period the following legislative acts, amending Directive 
2001/83/EC and Regulation No. 726/2004, were approved by EC: 
 Directive 2010/84/EU of 15 December 2010 – amending Directive 
2001/83/EC in order strengthen EU law in pharmacovigilance; 
 Regulation (EU) No. 1235/2010 of 15 December 2010 – amending and 
Regulation No, 726/2004 in order strengthen EU law in 
pharmacovigilance;; 
 Commission Implementing Regulation (EU) No. 520/2012 of 19 June 
2012 – provisions on the implementations of MAHs’ pharmacovigilance 
systems and provisions about the content and transmission of ADR 
reports, RMPs, PSURs and Post-Authorization Safety Studies; 
 Directive 2012/26/EU of 25 October 2012 – clarifying and strengthen EU 
actions related to safety concerns (e.g. Article 31 referrals, Urgent Union 
procedures); 
 Regulation (EU) No. 1027/2012 of 25 October 2012 – provisions about 
the list of medicinal products that are subject to additional monitoring and 
the procedure to be followed by MAHs when suspending, withdrawing or 
not renewing an MA. 
This reform was made in order to improve and strengthen European 
pharmacovigilance network, to improve communication with healthcare 
professionals and to enhance the participation of healthcare professionals and 
society in general in the discussion of medicinal products safety. Also the roles 
and responsibilities of all parties involved were adapted in order to accomplish 
these objectives (15, 16). 
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In order to comply with Article 108a of Directive 2001/83/EC, as emended by 
Directive 2010/84/EU, EMA developed in cooperation with other competent 
authorities and other interested parties a series of guidance documents to help 
MAHs and competent authorities implementing pharmacovigilance 
requirements (5, 17). Those documents are known as Good Pharmacovigilance 
Practices (GVP). Since July 2012, when the first seven modules related to 
prioritised processes were released, EMA launched thirteen of a total of sixteen 
GVP modules. (17). 
Following the publication of Regulation (EC) No. 726/2004, as stated in Article 
55, EMA became responsible for the coordination of all scientific resources 
available in all Member States regarding the evaluation, supervision and 
pharmacovigilance of medicinal products in EEA. Pharmacovigilance and Risk 
Assessment Committee (PRAC) was established in July of 2012 in order to 
support the Committee for Medicinal Products for Human Use (CHMP) activities 
related to safety issues (18, 19). PRAC mandate covers the following 
procedures (19, 20): 
 Supervision of all aspects related to the risk management of the use of 
medicines (e.g. Periodic safety update reports (PSUR) evaluation and 
signal detection and evaluation); 
 Evaluation of protocol and results of post-authorisation safety studies; 
 Advice about Eudravigilance database functionalities; 
 Advice about medicines under additional monitoring; 
 Recommendations about pharmacovigilance issues at request of CHMP 
and CMDh. 
Pharmacovigilance presents over fifty years of history. It is a science that 
emerged from the need for better safety conditions when using medicinal 
products. Over this period several reforms occurred in this field focusing public 
health protection. Individualising the European case, in recent years several 
major reforms took place in order to adapt current demands for safe medicinal 
products, reshaping the roles of MAHs, authorities and civil society to 
accomplish this purpose.  
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1.3.3 Adverse Drug Reactions 
As referred previously, the beginning of pharmacovigilance is based on the 
thalidomide’s scandal. In the beginning of 1960’s decade, reports of several 
birth defects related to thalidomide’s use, especially phocomelia, make people 
questioning about the safety of this medicine. In the case described, 
phocomelia reactions on new-borns were the element that made possible to 
evaluate the thalidomide’s safety. These elements are called ADRs. 
According to the current definition, an ADR is “a response to a medicinal 
product which is noxious and unintended” (5). Concerning the “response to a 
medical product” it should be referred that this response should present a 
causality relation with the medicinal product use (clearly established by 
scientific methodologies) (21). 
According to Article 2 of the Directive 2001/20/EC, an AE is “Any untoward 
medical occurrence in a patient or clinical trial subject administered a medicinal 
product and which does not necessarily have a causal relationship with this 
treatment” (4, p4),  (22). Therefore, reports of adverse reactions really caused 
by the medicine and reports adverse events can occur when using a medicinal 
product. 
According to the Module VI of GVPs, AE received should only be validated by 
determining (23): the identity of reporter; an identifiable patient; an identifiable 
medicine identifiable; and a suspected reaction. 
After these elements had been fully validated the causal relationship between 
AE and medicinal product can be then evaluated. In the case of a positive 
causal relationship of an AE received by the sponsor, the reaction may or may 
not be reported the authorities, depending on its seriousness assessment (24). 
In a following section this process will be described in more detail. 
Based on the seriousness, and ADR can be classified as serious or non-
serious. An ADR is classified as serious if one of the following outcomes 
occurred: 
 Death;  
 Life-threatening condition;  
 Requires inpatient hospitalisation or prolongation of existing 
hospitalization;  
 Results in persistent or significant disability or incapacity; 
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 Congenital anomaly/birth defect. 
Any other ADR that result in other outcomes and not above mentioned, it should 
be classified as non-serious. 
 
In the industry, other important classification systems used are those related to 
causality assessment. One the most used causality system is the Naranjo’s 
scale. According to the causal relation of the ADR with the suspected medicinal 
product, the ADR can be classified into (25): 
 Definite 
 Probable 
 Possible 
 Doubtful 
 
In a more academic view, ADRs can be classified on several types, depending 
on the relation with the dose and/or the onset of the reaction. One on the most 
widely used classification system categorizes ADRs on seven types: from type 
A to type F as described in Table 2 (26).  
 
Table 2 – Classification of adverse drug reactions (26) 
Type of reaction Features 
A: Dose-related  
(Augmented) 
Common 
Related to a pharmacological action of 
the drug 
Predictable 
Low Mortality 
B: Non-dose-related  
(Bizarre) 
Uncommon 
Not related to a pharmacological action of 
the drug 
Unpredictable 
High Mortality 
C: Dose-related and time-related 
(Chronic) 
Uncommon 
Related to the cumulative dose 
  
University of Aveiro                                       Master in Pharmaceutical Medicine 
Page | 18  
 
Type of reaction Features 
D: Time-related  
(Delayed) 
Uncommon 
Usually dose-related 
Occurs or becomes apparent sometime 
after the use of the drug 
E: Withdrawal  
(End of use) 
Uncommon 
Occurs soon after withdrawal of the drug 
F: Unexpected failure of therapy 
(Failure) 
Common 
Dose-related 
Often caused by drug interactions 
 
As conclusion, when using a medicinal product deleterious effects may occur 
that might or might not be related to the medicine. The knowledge of the 
occurrence of such adverse reactions may change the safety profile of a 
medicinal product. Those changes may lead to a shift in risk-benefit ratio. When 
this occur, MAHs need to preform appropriate actions in order to re-assure a 
positive risk-benefit ratio, which my pass through a simple update of products 
information to withdraw the product from the market. Therefore, MAHs should 
be aware of the occurrence of safety issues related to their products. 
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1.4 Host Company – Bluepharma 
 
Bluepharma – Indústria Farmacêutica, S.A., hereafter referred as Bluepharma, 
history starts in February of 2001, after the acquisition of a Bayer’s industrial 
unit. Bluepharma is a Small and Medium Enterprise based in Coimbra. 
Blupharma’s activities are centralized in three main fields: 
 Producing pharmaceutical drugs for Bluepharma and other 
companies; 
 Research, development and registration of pharmaceutical drugs; 
 Marketing of generic pharmaceuticals. 
 
Figure 5 – Bluepharma’s building 
 
In the last thirteen years, several moments have contributed to the sustainable 
growth of Bluepharma. Some of the most important were the following: 
 Foundation of Bluepharma Genéricos – Comércio de Medicamentos, 
S.A., in 2002 – responsible for the commercialization of medicinal 
products under Bluepharma brand; 
 Inauguration of the Research and Development Center, in 2003 – 
Bluepharma gained the ability to manufacture new products within its 
facilities; 
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 Certifications of ISO 9001, 14001 OHSAS 18001 and EMAS, in 2003 – 
first Portuguese pharmaceutical company to acquire integrated 
certification; 
 Launch of the first medicine developed at Bluepharma, in 2008 - ; 
 Food and Drug Administration certification, in 2009 – first Portuguese 
pharmaceutical company allowed to produce medicinal products for US 
market; 
 Inauguration of Bluepharma’s new facilities, in 2010 – allowed an 
increase of Bluepharma’s activities; 
 Inauguration of Blueclinical, 2012 – allowed Bluepharma to extend its 
development activities and to sponsor its own clinical studies. 
As above mentioned, in 2002 Bluepharma Genéricos – Comércio de 
Medicamentos, S.A. (thereafter referred as Bluepharma Genéricos) was 
founded. Bluepharma Genéricos holds the MA of the most part of the 
Bluepharma group portfolio in Portugal. Currently, Bluepharma Genéricos has a 
portfolio with nearly seventy generic medicinal products, and it is a distributor 
for two medical devices and one cosmetic product.  
Bluepharma portfolio only includes nearly ten products. Therefore, 
Bluepharma’s Pharmacovigilance activities are mainly related to Bluepharma 
Genéricos products. 
Bluepharma group also includes companies related to the development of 
innovative products. Luzitin, SA and Treat-U are two spin-offs related to the 
development of new alternatives to oncology treatments. These spin-offs 
derived from the close relationship with the academia, which was one the 
factors that were on the genesis of the creation of the Bluepharma. 
 
Bluepharma structure comprises several distinct departments. During my 
internship I was allocated to Regulatory Affairs & Pharmacovigilance. This 
department is responsible for: 
 Submission and management of MAA; 
 Management of approved MA; 
 Support activities related to the marketing of medicinal products; 
 Preparation of regulatory documentation;  
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 Pharmacovigilance; 
 Scientific Service; 
 Cosmetics and Medical Devices registration and dossier management. 
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2 INTERNSHIP EXPERIENCE 
 
My experience in Bluepharma was focused on the activities performed in 
Regulatory Affairs & Pharmacovigilance Department, in particular the activities 
related to pharmacovigilance. However, I had the opportunity to learn the 
activities performed in other departments. Either by participating in companies 
activities either by attending to in-house training sessions, I had contact with 
several other departments of Bluepharma. In this section, I will start to describe 
my internal training program during my internship. In sub-section 2.2 I will 
describe the pharmacovigilance activities in that I was involved. In sub-sections 
2.3, 2.4 and 2.5 I will describe the activities related to regulatory affairs, 
cosmetics and scientific service, respectively, in which I participate. 
 
2.1 Experience on Several Departments of Bluepharma 
 
As referred in the previous section, Bluepharma has several certifications. In 
order to comply with some requirements necessary to maintain those 
certifications, Bluepharma’s collaborators have to attend to several specific 
training sessions. Therefore, during my internship I attended to several in-house 
training sessions, some of them mandatory and others inserted in my own 
training program. Moreover, this allowed me to follow the activities developed in 
several departments for one day, besides Regulatory Affairs & 
Pharmacovigilance department. 
 
As any other new collaborator in Bluepharma I started my internship in 
Bluepharma by reading Bluepharma’s integration manual for new collaborators, 
where a description of Bluepharma is made and general internal rules are 
described. Also, I attended to a one-day training session involving the following 
themes: 
 Bluepharma’s Quality Management System; 
 Innovation and Research and Development certification; 
 Environment and safety management system; 
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 Good Manufacturing Practices; 
 CTD contents and regulatory requirements; 
 Information technology services; 
 Pharmacovigilance. 
As referred before, I had the opportunity to follow the activities several 
Bluepharma’s departments: 
 Research and Development 
 Business Development 
 Production and Packaging 
 Quality Control 
 Product Quality & Compliance 
 Quality Management 
In this section I will describe the learnings obtained during these training 
sessions. 
  
2.1.1 Research and Development 
Located in the Research and Development building, the this department 
encompasses several activities related to the manufacture of new products and 
with post-marketing related activities. The department is structured in three 
different sections: 
 Galenical development – responsible for the development of new 
products at a sub-industrial scale,  by testing several formulations; 
 Analytical development – responsible for the Bioavailablity studies for 
new Bluepharma’s products; 
 Stabilities – responsible for testing Bluepharma’s products under 
several ICH stability conditions necessary for MAA and shelf-life data. 
In this training session I had the opportunity to be in contact with the laboratory 
activities performed within a pharmaceutical company. This allowed me to 
understand their relevance for medicinal products quality.  
I also had the opportunity to obtain a better understanding on some concepts 
that I generally observe on medicinal products dossier, such as the dissolution 
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profile, and their relevance during the development of new generic medicinal 
products.  
During this training session, I noted that this is a very crowded environment, 
with several people occupying a large section of laboratory benches. Although it 
may appear a cluttered environment, I had the chance verify that every person 
and every equipment has specific tasks and that laboratory chiefs manage their 
activities.  
 
2.1.2 Business Development 
I had the chance to attend a training session in Bluepharma’s Business 
Development department. During this training session I learned what 
Bluepharma’s business pillars are. The three main business areas developed in 
Bluepharma are: Licensing of technology (either by the acquisition of 
technologies external to Bluepharma the so called “licensing-in”, or by 
Licensing-out, this is by licensing its own developed technology), by exporting 
its own brand and branded products through distribution contracts and also 
gathering manufacture contracts that allow Bluepharma to handle and 
manufacture at Bluepharma’s facilities third party products as a service. This 
business area is commonly referred in the pharma industry as Contract 
Manufacturing or Third Party Manufacturing. This last business area is still one 
of the key business activities of Bluepharma in the present day.  
I also learned that the Business Development department has a very 
transversal role in the research and development activities associated to a 
specific project. The influence of the department depends very much on which 
stage of product development the project is. These activities vary from 
Intellectual Property review and screening, procurement of active 
pharmaceutical ingredient manufacturers during development phase, to find 
partners during clinical and application phase to whom license the product or 
even to search for joint ventures or co-development opportunities to take place 
between Bluepharma and a 3rd party in order to mitigate risks and costs 
allocated to a specific project or simply to strengthen it by exploring synergies 
between different companies.  
  
University of Aveiro                                       Master in Pharmaceutical Medicine 
Page | 26  
 
The Business Development department is also responsible for the application 
for reimbursement of the new products intended to the Portuguese market. 
 
My experience in Business Development Department allowed me to conclude 
that this is a very pro-active department, since persons working in this 
department are expected to find and maintain new business opportunities for 
Bluepharma. Also, in contrast with my expectations, a broader range of 
activities a related to this department. However, as I observe during daily 
practice, the activities performed by Business Development department most of 
the time require regulatory support, which requires constant contact between 
the two departments. 
 
2.1.3 Planning and Production Management – Panning and Purchasing 
Planning and Production Management department is responsible for planning 
how orders received from customers are to be managed.  
Planning and Production Management department structure encompasses two 
distinct sectors: 
 Planning and Purchasing – responsible for contact with Bluepharma’s 
customers and suppliers; 
 Production Management – responsible for the management of 
production activities and equipment maintenance. 
In this section I will only describe my learning related to the first sector 
(Planning and Purchasing). Production Management activities will be presented 
on section “Planning and Production Management – Production Management”. 
 
During my training session in this sector I had the opportunity to observe how a 
new order received from a costumer is processed. After a new order is received 
by Planning and Purchasing sector a new entry is created on Systems, 
Applications & Products (SAP) software.  This software system, by analysing 
the records of raw materials present in Bluepharma at the time, generates an 
alert, listing the raw materials that exist and those that are missing to fulfil the 
order. 
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It is responsibility of Planning and Purchasing sector to manage the stock of raw 
materials in Bluepharma. Therefore, when a raw material is missing a member 
of this sector will enter in contact with suppliers in order to obtain the needed 
raw material.  
As I observed, some raw materials have a short shelf-life and therefore there is 
only a small window of opportunity to be used during production activities. This 
means that Planning and Purchasing and Production sectors should have their 
activities coordinated in order to maximize the use of those raw materials and 
avoid the loss of resources. 
For raw materials that are used in a huge set of production activities, or have a 
long shelf-life, their stock should be maintained stable throughout production 
activities. I observed how these stocks of raw materials are managed and 
understand the implications of their missing. If they are missing, several 
productions activities may be delayed, which could have impact on 
Bluepharma’s future contracts. 
 
Defining the final format of packaging materials (primary and secondary) is one 
the activities performed by this sector. I had the opportunity to observe how this 
activity is performed. When a new product is intended to be packaged in 
Bluepharma, packaging dimensions have to comply with client’s standards and 
feasible to be packaged with Bluepharma’s equipment. To accomplish this, a 
series of draft versions, known as “proofs”, is exchanged between Planning and 
Purchasing and client representatives, until a final version is agreed. An entry 
with this final version is created on SAP system that will be accessed by 
packaging when preforming their tasks. 
 
This training session allowed me to be in contact with raw materials stock 
management inside a pharmaceutical company. I got the chance to understand 
the importance of centralizing this service inside a company, since it can save 
resources by obtaining better supplying contracts. Also, I observe how final 
format of packaging materials is obtained. This training session also allowed me 
to understand how regulatory activities that I perform in my daily practices may 
affect the activities of other departments. This department presented me a very 
dynamic team since all members have to coordinate their tasks between them 
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and Production and Packaging sectors in order to comply with clients’ orders on 
time. 
 
2.1.4 Planning and Production Management – Production Management 
As referred above, Planning and Production Management department is divided 
is two distinct sectors. Production Management sector encompasses activities 
related to production, packaging and equipment maintenance. 
During my internship I had the opportunity to attend to training sections related 
to the production and packaging of medicinal products in Bluepharma. Although 
I did not have contact with equipment maintenance activities, in a presentation 
explaining Planning and Production Management department’s activities, I got 
the chance to understand that these activities are related to production and 
packaging equipment maintenance. Also, the maintenance crew is responsible 
for adapting Bluepharma’s machinery in order to comply with special requests 
from clients, such as special marks on tablets. 
 
In this sector I attended to training sessions related to production and packaging 
activities performed by Bluepharma. 
Bluepharma is licensed to produce several types of pharmaceutical forms. This 
includes: tablets, film-coated tablets, orodispersible tablets, hard capsules and 
oral liquids. 
During this training session I observed that Bluepharma’s production equipment 
is able to perform the following processes: 
 Weighing; 
 Granulation; 
 Compression; 
 Coating; 
 Capsule filling. 
After a client’s order is inserted on SAP system by Planning and Purchasing 
sector, an alert is receive by production crew. Based on the alerts received, the 
responsible for production, in collaboration with PGP director and packaging 
responsible, will schedule the fulfilment of client’s order. 
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After the production phase is over, two situations may occur: Bluepharma’s is 
responsible for final packaging, or final packaging is not to be performed by 
Bluepharma. 
As I observed, when Bluepharma is not responsible for final packaging, the 
finished product is stored in jerrycans and sent to warehouse. If Bluepharma is 
responsible for final packaging, finished product is sent packaging area. 
 
During this training session, I had the opportunity to observe packaging 
processes applied in Bluepharma. Bluepharma’s packaging equipment includes 
automatic machinery able to fill several types of blisters with tablets or capsules. 
The responsible for packaging, as the production responsible, has to schedule 
packaging activities. This will allow packaging finished product almost 
immediately it is received. 
After consulting SAP system, the responsible orders the packaging crew to 
prepare the machinery in accordance with product specifications. As I observed, 
this is a very consuming process and sometimes an eight hour shift may be 
needed to clean and prepare the machinery. 
After the finished products is packaged an entry is created on SAP system, and 
the product is sent to warehouse. 
  
With this experience I got a better look on the steps needed to fulfill an order 
from a client. Regarding production and packaging steps, I observed that these 
steps involves several people, from department directors to machinery 
operators. A high level of coordination between all collaborators involved is 
needed in order to avoid delays in the processes. 
 
2.1.5 Quality Control 
In a one-day training session in Quality Control department, I had the 
opportunity to follow the activities performed within the scope of this 
department. I learned that Quality Control department is responsible for 
analysing every raw-material (active pharmaceutical ingredients, excipients and 
packaging materials), bulk or finish product that arrives and every bulk or finish 
product before it is sent to costumers.  
  
University of Aveiro                                       Master in Pharmaceutical Medicine 
Page | 30  
 
I followed a member of Quality Control department during a sampling process 
for a product prior to its release. The procedure started with an alert received in 
Quality Control department through SAP system. After the identification of the 
jerrycans containing the product, I observed how the product was transferred to 
a room with controlled environment. In this room, an entry in SAP system was 
made recording the start of the procedure. After that, the jerrycans were open in 
a specific way, in order to avoid contamination of the tablets. Next, visual 
checking of the tablets was performed in all jerrycans. A sampling of a few 
tablets from four jerrycans was performed. The jerrycans were sampling was 
performed were chosen based on the phase of production the tablets were 
produced. After completing the sampling procedure, the jerrycans were closed 
and retrieved from the room. 
The samples collected from the jerrycans were sent to Quality Control 
department laboratory in order to perform analytical and microbiological testing. 
 
Microbiological testing is also a responsibility of Quality Control department 
department. During my training session in Quality Control department I observe 
how microbiology testing is performed in Bluepharma.  
This visit allowed me to understand how quality control of products in 
Bluepharma is performed. I observe that there are many laboratory tests that 
need to be conducted in order to ensure that a product has high levels of quality 
prior to its release.  
Regarding department’s equipment, I observed that many times the equipment 
is shared were other departments, such as Research and Development 
department. This is a way to maximize the use of the equipment. However, if 
the activities of the different departments are not coordinated, delays in the 
processes may occur, which could have impact on company’s commitments to 
its clients and/or partners. 
 
2.1.6 Product Quality & Compliance 
Product Quality & Compliance (PQ&C) department is responsible for verifying 
products compliance with internal and/or costumers standards. A Qualified 
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Person is responsible for PQ&C management. This Qualified Person is also 
responsible for batch release in Bluepharma. 
During my training session in PQ&C, I learned what activities are developed 
within the scope of this department. Those activities include: change control 
generation for equipment specification, equipment calibration/qualification-
related activities, management of medicinal product technical documentation, 
review of documentation related to product production and packaging, Product 
Quality Reviews, product quality complain management and several other 
activities. 
 
As referred, the Qualified Person is responsible for batch release; this means 
that Qualified Person confirms the compliance of the product with technical 
specifications. Through verifying documentation from Production, Packaging 
and Quality Control department, PQ&C produce a document known as 
Certificate of Release. If no non-conformities were found, our Qualified Person 
approves the Certificate of Release and the product is released. 
 
Before this training session I had no idea the quantity of documentation that is 
needed to prove that a product is compliant with technical specifications. During 
this training session I understand that this department needs to be in constant 
communication with several other departments, since data necessary for 
product’s quality review is originated form several departments. Also, several 
documentations produced by this department are necessary to complete 
numerous tasks on other department. 
 
2.1.7 Quality Management 
Bluepharma’s Quality Management department encompasses the following 
major responsabilities: 
 Work and Environmental safety; 
 Site Master File management; 
 Bluepharma’s Quality Manual management; 
 Audit managment; 
 Certificate emission (e.g. Halal certificates); 
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 Management of Bluepharma’s internal documentation. 
 Supplier qualification; 
 Collaborators training management. 
During training session in this department it got the opportunity to understand 
how this department is structured and how the tasks above listed are 
performed.  
Regarding the management of Bluepharma’s internal documentation I observed 
that this is made using the software Ennov®. This software allows distributing 
documentation in two different levels: 
 Standard Operation Procedures; 
 Forms. 
Although is responsibility of each department to maintain their documentation 
up-to-date, it is Quality Management department responsibility to code them on  
Ennov® and them distribute the documentation to all relevant parties.  
 
Several valuable learnings were acquired with this training session. First, I 
learned that this department is responsible for several tasks with the aim to 
confirm the high quality of Bluepharma’s internal documentation. With this 
training session, I obtained a deeper knowledge on how Bluepharma’s internal 
documentation is managed and keep up-to-date. Also, I learned how to use the 
Ennov® software, which was very important for my daily activities since I have 
to access to several procedures when performing my tasks.  
During this session, I observed how Bluepharma’s complies with its 
commitment with environmental responsibility, through activities such as 
pharmaceutical residue processing. I also learned how Quality Management 
department manages to comply with health and training requirements of 
Bluepharma’s collaborators. 
At the end of this session I concluded that although this is not a very crowded 
department, Quality Management department encompasses a high variety of 
activities. These activities also have a central role on the recognition of the 
quality of Bluepharma’s services. 
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2.2 Pharmacovigilance Activities performed 
 
Pharmacovigilance field presents a significant set of activities that need to be 
fulfilled in order to ensure the safe use of medicinal products and ultimately 
allowing MAHs to maintain their MAs. For some activities, as I will present, 
generic medicines have their pharmacovigilance responsibilities streamline, in 
line with risk proportionality rule. In the following section, I will describe several 
pharmacovigilance activities in which I was involved during my internship. Since 
Bluepharma only has generic medicine MAs, some of the presented activities 
will be adapted to generics reality. 
 
2.2.1 Pharmacovigilance System 
In a way that a MAH can fulfil its pharmacovigilance obligations, the MAH 
should operate and manage a Pharmacovigilance System, maintaining it always 
up-to-date. In accordance with Article 104(3) of Directive 2001/83/EC, this 
Pharmacovigilance System should (5, 27): 
 Have permanently and continuously at his disposal an appropriately EU-
QPPV; 
 Maintain and make available on request a Pharmacovigilance System 
Master File (PhSMF); 
 Operate a risk management system for each medicinal product; 
 Monitor the outcome of risk minimisation measures; 
 Update the risk management system and monitor pharmacovigilance 
data to determine whether there are new risks or whether risks have 
changed or whether there are changes to the benefit-risk balance of 
medicinal products. 
The EU-QPPV, the contact point for all pharmacovigilance matters, has the 
main role of managing company’s pharmacovigilance system. In accordance 
with current pharmacovigilance legislation, MAHs should have a written 
document detailing all the activities performed within the scope of 
pharmacovigilance inside the company. This document is known as 
Pharmacovigilance System Master File (PhSMF) (5, 27, 28). 
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Like any other MAH, Bluepharma as a PhSMF implemented. This PhSMF 
describes the pharmacovigilance system for Bluepharma and Bluepharma 
Genéricos. 
 
On this section I will explain the concept of PhSMF location and I will describe 
the document’s structure. As any other system, Bluepharma’s 
pharmacovigilance system has to be continuously monitored. Therefore, I will 
end this section describing how the performance of this system is evaluated. 
 
Location 
Current guidelines suggest that PhSMF should be located at the site where 
main pharmacovigilance activities are performed or at the site where the 
qualified person responsible for pharmacovigilance operates. This place shall 
ensure that EU-QPPV has a permanent access to it (28, 29).  
Bluepharma’s pharmacovigilance activities are performed in Bluepharma’s 
building. Therefore, in compliance with authorities’ recommendations, 
Bluepharma’s PhSMF is located in Bluepharma’s building. 
 
Structure of PhSMF 
PhSMF is a complex document. Due to the distinct nature of PhSMF sections, 
this document should include two distinct parts: primary topic section and 
annexes. No template for PhSMF content had been provided by authorities. 
However, some guidance regarding its structure is provided on Article 2 of 
Commission Implementing Regulation No 520/2012 and on Module II of GVPs 
(28, 29).  
The primary topic section should contain information that is fundamental to the 
description of pharmacovigilance system. In accordance with Article 2 of 
Commission Implementing Regulation No 520/2012 this should contain (29): 
 Information regarding EU-QPPV; 
 Description of MAH organizational structure; 
 Sources of safety data; 
 Computerised systems and databases; 
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 Pharmacovigilance processes; 
 Description how data is handled during pharmacovigilance activities; 
 Pharmacovigilance system performance; 
 Quality system; 
 Description of subcontracted services. 
On the other hand annexes should contain a detailed description regarding of 
pharmacovigilance activities. Annexes includes mainly two types of information: 
one encompassing more static information (such as certificates, declarations…) 
and the other encompassing more mutable information (such as performance 
indicators, product lists…). Based on authorities’ recommendations nine 
annexes shall be contained in PhSMF (28, 29): 
 Annex A – EU-QPPV related information (- should include a list of 
delegated tasks, Curriculum Vitae; 
 Annex B – The Organisational Structure of the MAH – should list exiting 
contracts; 
 Annex C – Sources of safety data – a list describing the sources of safety 
data; 
 Annex D – Computerised systems and Databases – section where 
computerized systems used in the pharmacovigilance system, if any; 
 Annex E – Pharmacovigilance Process, and written procedures – list of 
procedures used in pharmacovigilance activities; 
 Annex F – Pharmacovigilance System Performance – list of indicators 
used to assess system and current results; 
 Annex G – Quality System – list of audits scheduled, conducted and/or 
completed; 
 Annex H – Products – list of products that under the scope of the 
pharmacovigilance system; 
 Annex I – Document and Record Control – logbook listing the changes 
that occurred in the PhSMF annexes. 
By the nature of the mutable information contained in annexes, it would be 
impracticable to track all the changes performed in a PhSMF. Therefore, all 
changes performed in annexes are recorded in the logbook present in Annex I. 
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Assessment of the Pharmacovigilance System 
In order comply with Article 2 of Commission Implementing Regulation No. 
520/2012 MAHs should include in their PhSMF a description of process used 
for monitoring the performance of the pharmacovigilance system (29). On 
PhSMF section “Pharmacovigilance system performance” the MAH should at 
least describe (28): 
 The evaluation system used to assess the correct reporting of ICSRs; 
 The metrics used to monitor the quality of submissions and performance 
of pharmacovigilance; 
 How PSUR submission to authorities is monitored; 
 How variation submissions are monitored; 
 How Risk Management Plans commitments, if any, are monitored; 
 Other metrics used to evaluate the performance of the system. 
In accordance with Article 9 of the same regulation, MAHs may use 
performance indicators to evaluate the performance of the system (29). In 
Bluepharma’s PhSMF a list of performance indicators is present on Annex F. 
This list is composed by the following indicators: 
 
Table 3 – Performance Indicators used in Bluepharma pharmacovigilance system 
Type of Performance 
Indicator 
Performance Indicator 
ADR/AE input management 
 Rate (%) of received ADR/AE per source 
 Average time needed for validation decision 
Literature Research 
 Rate (%) of literature researches 
 Rate (%) of processed literature research cases 
 Rate (%) of valid ADR originated from literature 
research 
 
Management of valid ADR 
 Rate (%) of valid ADR/AE per source 
 Rate (%) of valid ADR occurred in EU 
 Rate (%) serious ADR 
 Rate (%) non-serious ADR 
 Rate (%) of compliance on notification 
processes 
 Rate (%) of compliance on notification deadlines 
 
PSUR  Rate (%) of compliance on PSUR submissions 
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Type of Performance 
Indicator 
Performance Indicator 
 Rate (%) of compliance on PSUR submission 
deadlines 
 Rate (%) of synchronized PSUR 
 Average time needed for PSUR submission upon 
the Data Lock Point (± Standard Deviation) 
Risk Management Plan  
(RMP) 
 Rate (%) of medicinal products with RMP 
 Rate (%) of RMP with “Risk minimization 
measures” 
 Rate (%) of compliance on RMP updates 
 Rate (%) of compliance on RMP updates 
deadlines 
Safety variations 
 Rate (%) of safety variations 
 Rate (%) of compliance on safety variations 
submission deadlines 
Signal detection  Rate (%) of signal detections 
Security measures 
 Number of security measures per year 
 Number of DHCP per year 
 
During my internship, one of my tasks was to create in a three-month period 
basis a report evaluating Bluepharma’s Pharmacovigilance system in the 
previous three-months, using the above mentioned indicators. After extracting 
data from relevant internal data-loggers and using an already established 
template, I elaborated a report presenting the results of the system performance 
in the concerned period. This report is then reviewed and signed by 
Bluepharma’s EU-QPPV. The signed version of the report is substitutes the 
previous version present on Annex F of PhSMF . 
 
This was a very rewarding experience for me. Doing this I had the chance to 
participate in the evaluation of Bluepharma’s pharmacovigilance system. With 
this activity I had the opportunity to observe which activities are performed in 
Bluepharma related to pharmacovigilance.  
Another important finding for me is that for several activities the compliance rate 
must be 100%. If the value obtained is under this value, this mean that 
Bluepharma did not comply with its pharmacovigilance activities.  
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In the course of time MAHs responsibilities might change. This may lead to the 
elaboration of new indicators in order to monitor the compliance with a new 
specific responsibility. Or, in other hand, an indicator may become obsolete and 
be withdrawn from the assessment. 
By analysing the data I get the opportunity to be involved in Bluepharma’s 
pharmacovigilance system management. The information extracted from 
performance indicators contributes for the continuous improvement of the 
system. Consequently, systems performance is improved. 
 
2.2.2 Changes in Legislation Monitoring 
As already proved, pharmacovigilance is a field with a very strong regulatory 
basis. Through regulations, directives or simply through guidance documents 
several entities publish documents that are relevant for the well conducting of 
pharmacovigilance activities. These entities might provide national, regional or 
even global guidance. 
With the development of new technologies or techniques, or even due to 
specific safety concerns, updates in regulatory documents provided by these 
entities might be published and have impact on pharmacovigilance activities. 
Therefore, it should be a priority for MAHs to develop and maintain a system 
allowing them to successfully monitor the publishing of such documents. 
Also, through a successful monitoring system of changes in pharmacovigilance 
legislation it will be possible to comply with Pharmacovigilance System quality 
present in Module I objective a: “Complying with the legal requirements for 
pharmacovigilance tasks and responsibilities” (5, p5) (30). 
 
Bluepharma, as referred previously, has an Investigation, Development and 
Innovation certification. One requirement necessary to maintain this certification 
is to prove that knowledge that arose from external sources, this is knowledge 
from entities outside Bluepharma and relevant for the internal activities, is not 
lost. Therefore, Bluepharma implemented a software system (InnovWay®) 
which allows the recording of vigilances that arose from the monitored entities 
and distribute those vigilances to the relevant parties inside Bluepharma. 
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Bluepharma is an EU based company with MAs are mostly approved in 
Portugal. Therefore, an exhaustive monitoring of the entities that might provide 
guidance for approved medicinal products in Portugal should be made. Those 
entities were monitored on a weekly basis.  
On below, I will list which entities are monitored and describe in detail how they 
are monitored. Also, I will describe how vigilances are created in order to 
comply with Investigation, Development and Innovation certification 
requirements. 
 
Portuguese Entities 
Being Bluepharma’s MAs present mostly in Portugal, the entities that are 
periodically monitored are those that might influence the pharmacovigilance 
activities performed in Portugal. It should also be referred that there is no official 
list of such entities, thus MAHs should act proactively finding those institutions. 
Locally entities, this is Portuguese entities; that are monitored are the following 
ones: 
 Portuguese Assembly; 
 Diário da República; 
 Infarmed, IP. 
 
Portuguese Assembly 
Portuguese Assembly is one of Portuguese sovereignty institutions. It is 
responsible for the development and approval of Portuguese laws. Also, since 
EU directives need to be incorporated into national legislation ("transposition"), 
the monitoring of Portuguese Assembly publications is crucial in order to know 
when the rules present in a new EU directive are applicable to Bluepharma’s 
MAs (31). 
In Bluepharma, this entity is regularly monitored by consulting its website and 
by monitoring daily publications of Diário da República. By monitoring On 
Assembly’s website it is possible to follow the developments on a new 
legislative act. For that, two tools present on the website are consulted: 
 Últimas Iniciativas Entradas – where new legislative acts to be discussed 
by Portuguese parliamentarians are listed (32); 
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 Últimos Textos Aprovados – where legislative acts approved by 
Portuguese parliamentarians are listed (33). 
The texts listed on Últimos Textos Aprovados need yet to be published on 
Diário da República in order to be considered official documents. Therefore, in 
Bluepharma, Diário da República’s website is also regularly monitored in order 
to known when new legislative acts applicable in Portugal came into force. This 
comprises the monitoring of both series that are updated on a daily basis (34): 
 Series A – comprising laws and decree-laws that were published; 
 Series B – comprising despatches, ordinances and other relevant official 
documents. 
 
Infarmed, IP 
Infarmed, IP is the Portuguese Competent Authority responsible for regulation 
and market surveillance of medicinal products, medical devices, homeopathic 
products and cosmetics. Therefore, it is essential be up-to-date with 
recommendations provided by this institution. Since laws are published by 
Portuguese Assembly, monitoring of Infarmed is intended to obtain further 
guidance from the laws published by Portuguese Assembly. 
The monitoring of this institution is made by consulting recent updates that were 
published in its website. For this, the tool present in the website “Mais 
Novidades” is consulted. However, this tool does not provide all the updates 
that have occurred in the pharmacovigilance field. Thus, the section of 
Infarmed’s website intended to provide guidance for pharmacovigilance 
activities is also periodically monitored. 
 
Regional Entities 
Regional entities, this is entities that act centrally in EU; that are monitored are: 
 European Medicines Agency; 
 Heads of Medicines Agencies; 
 European Commission; 
 European Parliament; 
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 European Consilium; 
 Official Journal of the European Union. 
 
European Commission, Parliament and Counsillium 
A legislative act in European Union level only becomes official after being 
published on Official Journal of the European Union. Therefore, as happens in 
for Diário da República, this journal is regularly monitored in order to known 
new legislative acts developed by European Union legislative institutions that 
might impact Bluepharma’s pharmacovigilance activities (35). 
However, MAHs should not be caught off guard when a new legislative act gets 
into force. Therefore, accompanying the discussions related to 
pharmacovigilance between EU legislative institutions is essential. 
 
Before showing how those institutions are monitored, I will summarize how an 
ordinary legislative act at EU level is conducted. On normal circumstances this 
process starts with a proposal for a legislative act being drawn up by European 
Commission. This proposal is sent to European Parliament where it is 
discussed and voted by European parliamentarians. If the proposal is adopted 
by the parliamentarians it is then sent to European Consilium. If adopted by the 
consilium the proposal is then published on Official Journal of the European 
Union, becoming this way an official document (35). 
 
Those proposals are monitored mainly through consultation of European 
Parliament’s database Legislative Observatory. By consulting this database it is 
possible for users to monitor the phase in which the document is being 
discussed and access to the most recent version of the document that is under 
discussion (36). However, in order to access other relevant documentation 
related to the legislative act that is being discussed, the official website of each 
institution is also monitored. 
 
European Medicines Agency 
As already referred on sections before, EMA is the EU institution that acts at a 
central level that is responsible for regulation, supervision and coordination of 
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pharmacovigilance activities (5). Therefore, this is another centrally entity acting 
that is monitored.  
Through monitoring its website tool What's New? it is possible for users to get 
access to all updates that have occurred in EMA’s website. This way MAHs get 
access to guidance documents that may affect its pharmacovigilance activities. 
 
Heads of Medicines Agencies 
The Heads of Medicines Agencies (HMA) is a network of the Heads of the 
National Competent Authorities whose organisations are responsible for the 
regulation of Medicinal Products for human and veterinary use in the EEA. 
Through its working groups HMA provide to MAHs several guidance documents 
that should be used when performing its activities (37).  
Since for centrally approved medicines these activities are already covered by 
EMA, the guidance documents provided by HMA are mainly intended for MAs 
granted by national procedures (i.e Mutual Recognition Procedure, 
Decentralised Procedure or purely national) (37). 
In Bluepharma, the monitoring of this entity is performed by consulting the tool 
present in HMA’s website What's new history that allows users to consult every 
updates that occurred in the HMA website in the previous six months (38). 
 
Global Entities 
Global entities that are monitored are: 
 International Conference on Harmonisation; 
 Council for International Organizations of Medical Sciences. 
 
International Conference on Harmonisation 
ICH is an entity created in 1990 that brings together the regulatory requirements 
of the three major markets for medicinal products: EU, Japan and the USA. It is 
ICH mission of harmonize the technical requirements for medicinal product 
registration. Therefore, MAHs should be aware of guidelines published, or 
updated by ICH. To do this, in Bluepharma ICH’s website was regularly 
monitored in order to get access to such guidelines. 
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Council for International Organizations of Medical Sciences 
CIOMS is another globally acting entity that provides relevant guidance for 
pharmacovigilance activities. As already referred before, this is an entity 
associated with WHO created in 1949 (see 1.3.2). In Blupharma, this entity was 
regularly monitored by consulting its website (39). 
 
Recording of vigilances 
During the process of monitoring an entity, documents with potential to affect 
pharmacovigilance activities might be detected. A reference for those 
documents is created on an internal data-logger for further assessment.  
After being evaluated, if a document is considered as being susceptible to affect 
pharmacovigilance activities in Bluepharma, an entry is also created on 
InnovWay® software. The entry created in this software will contain an 
assessment of the possible outcomes for pharmacovigilance activities. The 
entry created is then sent as an e-mail alert for all relevant Bluepharma’s 
collaborator.  
 
 
Figure 6 – InnovWay® vigilance record 
 
In conclusion, this is the process performed on Bluepharma to accomplish its 
objectives to comply with legal requirements and the internal Investigation, 
Development and Innovation objectives. This task allowed me to understand 
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that there are several institutions providing to MAHs guidance documents on 
how to conduct their activities. These institutions can, in certain instances, not 
only provide guidance for locally based MAHs but guidance in a worldwide 
scale. 
 
2.2.3 Risk Management System 
The use of a medicinal product is not exempted of risks, either identified or not. 
It is required for MAHs to maintain internal systems that allow the tracking of 
those risks. These systems are called Risk Management Systems. 
Therefore, a Risk Management System represents all the “activities and 
interventions designed to identify, characterise, prevent or minimise risks 
relating to a medicinal product, including the assessment of the effectiveness of 
those activities and interventions” (2001, p14), as stated on Article 1 of Directive 
2001/83/EC (5). 
The primary objective of the implementation of these systems is to ensure that 
the benefits of using a medicinal product outweigh the risks. As referred in 
GVPs Module V, this can be accomplished by increasing the benefits of using 
the medicinal product or by decreasing its risks, although Risk Management 
Systems are mainly designed to mitigate the risks (40). 
 
The cycle of risk mitigation, also known as risk management cycle (see Figure 
7), begins with the collection of safety data related to the medicinal product.  
After the analysis of those data a new safety concern (risk) related to the 
medicine use can be detected. This risk is then evaluated in order to determine 
if it has impact on risk-benefit balance. After the analysis, and if necessary, one 
or several measures can be defined as appropriate to deal with the risk 
identified. The most suitable are then applied, whose impact will be assessed 
posteriorly (40). 
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Figure 7 – The risk management cycle (40) 
The measures referred to be present on a Risk Management System are 
described on a document called RMP. On the following pages I will describe 
how a RMP is planned, developed and submitted to authorities. 
 
RMP planning 
When I arrived to Bluepharma, competent authorities were implementing new 
requirements related to the submission of RMPs and MAHs needed to comply 
with this new requirements. These requirements derived from the transposition 
to national legislation of the new requirements present on Directive No. 
2010/84/EC, amending Directive No. 2001/83/EC. 
 
MAHs were required the submission of the following documents: 
 Risk Management Plans; 
 Summary of Pharmacovigilance System. 
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Regarding the submission of RMPs, following the publication of Infarmed’s 
guidance, MAHs were required to submit an RMP for their products whose MAA 
was made after 21 July 2012 and do not present an RMP at the time. This had 
to be fulfilled until 27 December 2013. This also means that new MAA should 
present a RMP in section 1.8.2 of CTD (41). I receive the assignment to list all 
Bluepharma’s products that needed an RMP to be submitted. 
 
Summary of Pharmacovigilance System is a regulatory document that should 
be included in CTD’s sub-module 1.8.1 upon MAA (41). This document is a 
summary of applicant’s Pharmacovigilance System and should at least include 
the following (40): 
 Identification of EU-QPPV, including contact details; 
 Statement by applicant that it possesses all the necessary resources to 
fulfil its pharmacovigilance responsabilities; 
 Reference to PhSMF location. 
In contrast with the need for submission of an RMP, the Summary of 
Pharmacovigilance System has to be submitted for all MAH’s products upon 
product renewal or until 21 July 2015 through a variation, whichever first (41).  
In parallel with the assignment to determine which Bluepharma’s products 
needed the submission of a RMP, I also listed Bluepharma’s products that could 
have their Summary of Pharmacovigilance System submitted upon renewal or 
through a variation. 
 
RMP Development 
After consult all Bluepharma’s dossiers it was concluded that a RMP had to be 
submitted for one product. I had the chance to develop this RMP. During this 
activity I use the previously prepared Bluepharma’s template for RMPs. This 
template is in accordance with harmonized format of RMPs for applicants of 
generics applications should use. The development of this harmonized was 
intended to facilitate the RMP production by MAHs and its evaluation by the 
authorities (29). RMP structure is expected to have the following modules (40): 
 Part I: Product(s) overview 
 Part II: Safety specification 
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— Module SI: Epidemiology of the indication(s) and target 
population(s) 
— Module SII: Non-clinical part of the safety specification 
— Module SIII: Clinical trial exposure 
— Module SIV: Populations not studied in clinical trials 
— Module SV: Post-authorisation experience 
— Module SVI: Additional EU requirements for the safety 
specification 
— Module SVII: Identified and potential risks 
— Module SVIII: Summary of the safety concerns 
 Part III: Pharmacovigilance plan 
 Part IV: Plans for post-authorisation efficacy studies 
 Part V: Risk minimisation measures (including evaluation of the 
effectiveness of risk minimisation measures) 
 Part VI: Summary of the risk management plan 
 Part VII: Annexes 
Due to the principle of proportionality of risks, which states that Risk 
Management Systems should be proportionate to the potential and identified 
risks, the structure of RMPs for generic applications was streamlined  (5, 40). 
Therefore, as present on GVP Module V, RMP sub-modules SI to SVII may be 
omitted. Also Parts III and IV might be omitted if no additional 
pharmacovigilance or efficacy studies were imposed to the reference product 
(40). 
 
RMP production was based on the safety concerns identified for the medicinal 
product presented in reference product’s SmPC. Reference information for 
generics should be in accordance with its innovative’s reference information. 
Therefore, the risks identified for reference medicinal product should be the 
same for the generic medicinal product. In this sense, it is recommended  the 
use of reference product’s SmPC for describing the safety concerns identified 
during generic medicinal product  applications (18, 40). 
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Submission 
Regarding the submission of Summary of Pharmacovigilance System Infarmed 
requested the submission of variations for products needing a Summary of 
Pharmacovigilance System. However, an exception was created for products 
already in process of renewal at Infarmed. For those products Infarmed 
requested the submission of Summary of Pharmacovigilance System through e-
mail for renovacao.nacional@infarmed.pt, this way saving MAHs of paying the 
costs of a variation (41).  
The previously referred list for products’ Summary of Pharmacovigilance 
System also contained this variable. Through it I extracted a list of products that 
where already under renewal process. The list was then sent to the referred e-
mail with a cover letter requesting the inclusion of Bluepharma’s Summary of 
Pharmacovigilance System in the process. 
 
As referred before, a variation had to be submitted for the product whose RMP 
was needed. I got the change to understand how a variation is submitted. This 
variation was submitted as any other variation using Infarmed’s online platform 
for submission of variations (SMUH-ALTER) (42). In terms of variation 
classification the rules present on European Commission guidelines for 
variation classification were used. Based on those guidelines a Type II variation 
classified as “C.I.11 - Introduction of, or change(s) to, the obligations and 
conditions of a marketing authorisation, including the risk management plan” 
was submitted to Infarmed (43). 
 
In conclusion, the assignments presented on this section allowed me to obtain a 
better understanding of an RMP structure and content. Being Bluepharma’s 
products generics, this activity allowed me to understand the differences 
between a RMP for an innovative product and for a generic medicinal product. 
Since the risks identified in the RMP were the risks presented on innovative’s 
SmPC, this activity made me understand the importance of maintaining generic 
product information in line with reference product’s information.  .  
This activity also allowed me to be introduced into the rules governing the 
submission of variations. With the task involving Bluepharma’s Summary of 
Pharmacovigilance System I obtain a better knowledge about the structure and 
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content of this type of documents and the situations where they have to be 
submitted. 
 
2.2.4 Medical and Sicentific Literature Monitoring 
Following the Regulation (EC) Nº 726/2004 it was determined that a close 
monitoring of possible ADRs arousing from reports published in medical and 
scientific journals was needed. Therefore, in accordance with the Article 27 of 
this regulation: “the Agency shall monitor selected medical literature for reports 
of suspected adverse reactions to medicinal products containing certain active 
substances. It shall publish the list of active substances being monitored and 
the medical literature subject to this monitoring” (3, p30) (18). 
 
However, due to budget constraints, a draft list with active substances to be 
monitored by the Agency was only published in the beginning of 2014. In 
accordance with information provided by the Agency, the monitoring of scientific 
and medical literature for reports of suspected adverse reactions by the agency 
is expected to start in 2015 (44). 
 
Following the publication 2012 pharmacovigilance legislation, a series of 
guidelines aiming to support pharmacovigilance activities and replace Volume 
9A of Eudralex were launched. In Module VI (concerning the management and 
reporting of ADRs) provide guidance how MAHs should maintain a system to 
monitor ADR reports from literature during this transitional period (23, 45). 
As stated on GVP Module VI, literature reports are a significant source of safety 
information related to medicinal products. Therefore, it is expected MAHs to 
systematically and frequently (at least once per week) to monitor important 
databases of medical and literature references (such as Pubmed®). Also, local 
publication in journals non-indexed to those databases should be monitored. 
Through this procedures it is expected MAHs to become aware of safety 
concerns at a global and a local level (23). 
In this section I will explain in detail how monitoring of medical and scientific 
literature were performed in Bluepharma. For that purpose I will start to describe 
how the international database Pubmed® is monitored followed by a description 
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of the procedure applied to Portuguese non-indexed journals. The information 
regarding the process of validation of an Individual Case Safety Report (ICSR) 
will not be discussed in this section. On the section 2.2.5 I will describe this 
process in detail. 
 
International databases 
During my internship at Bluepharma’s pharmacovigilance sector one of my 
time-consuming tasks was the related to weekly systematic review of relevant 
medical and scientific literature recorded on the international citation database 
Pubmed® (46). In Bluepharma, it was choose to use this database because it is 
one the most largest international citation databases, and Pubmed® is one of 
the most used databases in pharmaceutical industry for bibliographic searches. 
Once a week (usually on Monday) an e-mail alert (for each product) is receive 
on pharmacovigilance system e-mail address with the citations recorded on 
Pubmed® during the previous week. This is possible using the My NCBI tool 
(see Figure 8) (47).  
 
The searches performed on Pubmed® were performed individually for each 
active substance as suggested by GVP guidelines. Searches performed using 
medicinal product name and active substance name would only give MAHs 
better recalls rates. However, to obtain better balances in the searches, this is 
more precise searches, more complex search algorithms using other search 
terms should be used (23). In Bluepharma, the search algorithm used had the 
following terms: 
 [Active substance]; 
 Adverse event; 
 Pregnancy 
 Overdose  
 Medication error  
 Off-label use  
 Misuse  
 Abuse  
 Occupational exposure 
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Figure 8 – My NCBI tool 
 
With this search algorithm it was expected to comply with GVP’s Module VI 
recommendations (23). When a new active substance is included on 
Bluepharma’s portfolio, a new entry for it is created on My NCBI and thereafter 
an e-mail alert for is receive every week. 
 
Non-indexed journals and abstracts from meetings 
Since international databases have a limited reach in terms of local 
publications, it is expected MAHs to have procedures in place to monitor 
medical and scientific publications in local journals where medicinal products 
have a marketing authorization (23). 
When I started reviewing medical and scientific literature in Bluepharma those 
procedures where still under development. Due to my previous experience in 
academic projects I was involved in their development. During that process I 
listed Portuguese journals (indexed and non-indexed journals) that were 
published in Portugal at that time. Based on the criteria of medical specialty 
discussed in each journal, a final list with seven journals related to the medical 
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specialty of Bluepharma portfolio was obtained. Therefore, the journals that I 
started to review were the following: 
 Revista de Fatores de Risco; 
 Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo; 
 Revista Portuguesa de Ortopedia e Traumatologia; 
 Sinapse; 
 GE - Jornal Português de Gastrenterologia; 
 Revista Portuguesa de Doenças Infecciosas; 
 Revista Portuguesa de Hipertensão e Risco Cardiovascular. 
However, due to the fact that most relevant meeting abstracts are not added to 
Pubmed® it was decide to monitor some Portuguese journals indexed to 
Pubmed®, in order to assess special publications with meeting abstracts. This 
was decided based on the fact that most relevant meeting abstract books are 
published on those journals. Thus, the journals whose special editions were 
monitored were the following: 
 Revista Portuguesa de Cardiologia; 
 Acta Médica Portuguesa; 
 Acta Reumatológica Portuguesa. 
 
In conclusion, this is the process performed in Bluepharma for reviewing 
relevant medical and scientific literature. Through being part of it I understand 
the importance of doing it to become aware of new safety concerns. It was also 
changeling to be involved in the development of procedures to monitor local 
publications, due to its specificities. 
 
2.2.5 Individual Case Safety Report 
When consuming a medicinal product a patient may suffer adverse events 
possibly related to the medicinal product. These suspected adverse reactions 
can be communicated to MAHs (23):  
 Directly by the patient; 
 By a third party, such as pharmacists or other health care professionals;  
 By a Competent Authority notification.  
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The information collected during these reports can be organized on documents 
with specific formats (e.g. CIOMS I form). These documents are specific to a 
reaction (or several) that happens to a patient in a specific moment. They are 
organized in a way that is possible to identify: the reporter(s), patient, 
reaction(s) and medicinal products suspected of causing the reaction (23). 
In accordance with Article 107 of Directive 2001/83/EC, MAHs should have a 
system to allow them to record all suspected adverse reactions that may be 
aware of, independently the reporter or the country of origin. However, as we 
will see next, not all the reports presented in this system need to be submitted 
to competent authorities. Also, the requirements for reporting will depend on the 
status of the medicinal product; this is if it already has a MA or if it is still an 
experimental product (5). 
With 2010 legislation the reporting system has also been updated. Due to 
improvements in Eudravigilance platform MAHs are now required to submit all 
reports of suspected adverse reactions electronically (independently of the type 
of MA procedure) (5, 23). 
In this section I will describe how a report of a suspected adverse reaction 
possibly related to a Bluepharma’s product is processed since it is received until 
is submitted to the Competent Authorities. 
 
Collection of reports 
Collection of AE reports can occur either from solicited reports, this is reports 
originated on organized data collection systems (e.g. clinical trials, non-
interventional studies), or from unsolicited sources, this is reports describing the 
occurrence of an AE on a specific patient and on a specific moment and not 
originated on organized systems of data collection. For purposes of this report, 
only AE reports derived for unsolicited sources are relevant (23). 
In accordance GVP module VI, there are four source types of unsolicited 
reports (23): 
1. Spontaneous reports – communication by a healthcare professional, or 
consumer to a competent authority, marketing authorisation holder or 
other organisation (e.g. Regional Pharmacovigilance Centre) that 
describes one or more suspected adverse reactions in a patient who was 
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given one or more medicinal products. In Bluepharma, sales 
representatives may also be a source of spontaneous report, if a 
suspected ADR to a Bluepharma product is reported to them during their 
visits; 
2. Literature reports – report of suspected adverse reactions from the 
scientific and medical literature; 
3. AE reports from internet or digital media – reports of suspected ADRs 
from digital media considered owned by the MAH; 
4. Reports from other sources 
During my internship in Bluepharma I learned what procedures are in place to 
receive/monitor suspected ADR reports from those sources. 
 
Validation of reports 
In the tasks that were allocated to me during my internship, validation of reports 
from literature reports was one the most time consuming. Those reports arose 
during the literature monitoring described on section 2.2.4. By analyzing the 
literature article I assess if it had all the validation criteria, and therefore 
qualified for reporting. These criteria are: 
 An identifiable reporter (name, initials or address); 
 An identifiable patient (initials, patient identification number, date of birth, 
age, age group or gender); 
 One or more suspected substance/medicinal product; 
 One or more suspected adverse reaction. 
 
Follow-up of reports 
Due to the fact that sometimes the information presented in suspected ADR 
reports may be incomplete, GVP module VI suggests MAHs to contact 
reporter(s) for further information regarding the ADR report. This is particularly 
important for monitoring events of special interest: prospective reports of 
pregnancy, cases notifying the death of a patient, cases reporting new risks or 
changes in the known risks.  
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In Bluepharma there are procedures in place in order to contact reporters when 
further details about a suspected ADR are needed. Those contacts may be 
performed through e-mail or telephone, accordingly with the contact available. 
During my internship I had the chance to observe how follow-up contacts are 
conducted and information retrieved from those contacts is recorded. 
 
Validated case assessment 
After case validation it is necessary to verify if the case will be effectively 
reported, and if so what information should be contained in the report. This is 
done in a step-by-step process by evaluating (48): 
1. Causality assessment. 
2. Relevance of the experience (e.g. expectedness, seriousness…); 
3. Codification of case-report; 
4. Quality of documentation (e.g. completeness of data, initial report vs 
follow-up report); 
During this evaluation (especially during the causality assessment) the following 
characteristics of the AE are taken into consideration (49): 
 Temporal relationship; 
 Outcomes of treatment suspension and/or re-challenge (if available); 
 Reaction profile: 
— Clinical and/or laboratorial manifestations; 
— Severity and intensity; 
— Frequency of reaction; 
— Possible mechanism of action; 
— Pre-disposing factors (e.g. basal diseases, concomitant 
medication…) 
 Pharmacological plausibility; 
 Supplementary data. 
In Bluepharma, two methods of causality assessment are used: 
 Naranjo’s scale; 
 Global Introspection. 
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Naranjo’s scale is performed by pharmacovigilance operators after a suspected 
ADR related to a Bluepharma’s product is validated. This method is based on a 
score system obtained from the evaluation of the suspected ADR in relation to a 
series of specific question (see Table 4). Based on the score obtained the 
causality of the reaction may be classified into (25):  
 Definite (score above 9); 
 Probable (score between 5 and 8); 
 Possible (score between 1 and 4); 
 Doubtful (equal to 0). 
 
Table 4 – Naranjo’s scale (25) 
Question Yes No NA Score 
1. Are there previous conclusive reports? 
+1 0 0 
 
2. Did the adverse event appear after the suspected drug was 
administered? +2 -1 0 
 
3. Did the adverse event improve when drug was discontinued or 
specific antagonist was administered? +1 0 0 
 
4. Reaction was more severe with increased dose or less severe 
with decreased dose? +1 0 0 
 
5. Did the reaction appear when the drug was readministered? +2 -1 0  
6. Are there other nondrug causes for the adverse event? 
-1 +2 0 
 
7. Did the reaction appear when a placebo was given? -1 +1 0  
8. Was a toxic serum concentration noted? 
+1 0 0 
 
9. Does patient have a history of similar reaction with drug or 
drug class? +1 0 0 
 
10. Adverse event confirmed by any objective evidence? +1 0 0  
Total Score  
 
 
Global Introspection is the algorithm followed by Pharmacovigilance sector 
associate physician to classify suspected ADR. This method involves clinical 
judgment about the suspected ADR. Based on this method, a suspected ADR 
can be classified into: 
 Certain; 
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 Probable; 
 Possible; 
 Unlikely; 
 Conditional; 
 Unassessable. 
 
During my internship, I participated in the evaluation of the suspected ADR 
report, including the assessment using the Naranjo’s scale. Product’s SmPC 
was used as reference information during this process. Additionally, with the 
information extracted from the report I filled the appropriate fields on an internal 
data-logger and a CIOMS I form, as required on internal procedures.  
 
Reporting of ICSRs 
During my internship in Bluepharma I participated in the submission of 
suspected ADR reports to competent authorities. In accordance with reporting 
requirements present on Article 107a (4) of Directive 2001/83/EC (as emended 
by Directive 2010/84/EC), MAHs shall report in no more than fifteen days after 
receiving the ADR report for serious ADRs and no more than ninety days for 
non-serious reactions (5). 
However, during transitional period, some competent authorities do not require 
the submission of reports of non-serious ADRs. Infarmed is one of those 
authorities (24).  
 
The ADR reports, as required on Article 172 of Decree-law 176/2006, were 
reported through EMA’s electronic platform Eudravigilance (see Figure 9) (50). 
In this platform there is a field allowing MAHs to choose which authority will 
receive the report. After selecting Infarmed and filling the appropriate fields 
related to the reaction description the report was sent. 
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Figure 9 – Eudravigivilance plataform 
After a message confirming the acceptance of the suspected ADR report by the 
authorities, a CIOMS I form with the information reported was retrieved from 
Eudravigilance. A paper copy of the article with a CIOMS I form with the 
information retrieved from Eudravigilance was then recorded on an appropriate 
file case in Bluepharma’s archive. 
 
With this activity I got the opportunity to obtain experience in the identification, 
validation and evaluation of suspected ADR reports. I also learned that for 
causality assessment, clinical judgment is in most cases needed to understand 
the relation between suspected ADR reports and the suspected medicine. By 
participating in the submission of suspected ADR reports I get the opportunity to 
be in contact with Eudravigilance platform.  
 
2.2.6 Periodic Safety Update Reports 
Portugal and European Union 
As laid down on Directive 2001/83/EC, one of post-marketing obligations of 
MAHs is the submission to competent authorities of Periodic Safety Update 
Reports (PSUR). PSURs are documents expected to discuss critically the 
safety and efficacy profile of a medicinal product taken into account the most 
up-to-date scientific evidence related to a medicinal product (5).  
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As present on Article 104 of Directive 2001/83/EC, PSURs should be submitted 
to competent authorities “immediately upon request or at least every six months 
during the first two years following the initial placing on the market and once a 
year for the following two years. Thereafter, the reports shall be submitted at 
three-yearly intervals, or immediately upon request” (2001, p92). With 2010 
pharmacovigilance legislation PSUR submission frequency for products 
containing some active substance had been levied with the publication of lists 
with union reference dates and frequency of PSUR submission. The influence 
of those lists on Bluepharma’s products is discussed below (5). 
 
The publication of 2012 pharmacovigilance legislation also had impact on 
PSUR-related activities. PSUR format had been harmonized in all EU member 
states, in order to facilitate the exchange of safety information between 
competent authorities. This new format also enhanced the identification and 
evaluation of safety concerns present on PSUR (29, 51). 
In the following sections I will describe the steps that are related to a PSUR 
since it is forecasted to be submitted until the MAH receive the outcomes from 
competent authorities’ evaluation. 
 
PSUR forecasted to be submitted 
When I started my internship at Bluepharma, PSURs frequency of submission 
were based on two lists, one from EMA and the other from HMA, which 
complements each other. Article 107e of Directive 2001/83/EC sets out that 
PSURs of products containing the same active ingredient but marketed in 
different member-states should be assessed by Single Assessment procedure; 
this is, PSURs will be jointly assessed by PRAC or by a member-state 
appointed by CMDh, depending on which list the product falls. The outcomes of 
PSUR assessment will be shared among all MAHs with products containing the 
active substance (5). 
 
It is present on Article 107c of Directive 2001/83/EC that products containing 
the same active ingredient but marketed in different member-states should have 
their PSUR submission frequency harmonized in order to make possible the 
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Single Assessment. To make this possible EMA regularly updates and 
publishes list of Union reference dates and frequency of submission of PSURs 
on its website. This is the first list whose publication I had to monitor. After its 
publication I had to evaluate if any change occur to previous versions that might 
impact Bluepharma’s products PSUR submission (5). 
 
However, not all active substances that are marketed in more than one 
member-state are in the above mentioned list. During the transitional period and 
until EMA has the capability the assess PSURs of all products under a national 
procedures, some active substances were temporarily allocated to a list 
managed by CMDh: List of Substances under PSUR Work Sharing Scheme 
and Other Substances contained in Nationally Authorised Products with Data 
Lock Point Synchronised (52). That’s the second list that whose publication I 
had to monitor and evaluate the impact on Bluepharma’s pharmacovigilance 
activities. 
 
Internally, the relevant sections for Bluepharma of both lists were compiled into 
a data-logger in order to facilitate the identification of PSUR submission 
frequencies for Bluepharma’s products. When changes occur in one of these 
lists affecting PSUR’s frequency of a Bluepharma product this data-logger is 
updated in accordance with the updated list. 
 
PSUR preparation and submission 
During my internship I had the opportunity to participate in the preparation and 
submission of PSURs. Although many Bluepharma’s products have waivers 
under Articles 10(1) and 10a of Directive 2001/83/EC to the obligation of 
submitting PSURs, there is still a significant list of Bluepharma’s products which 
requires the submission of PSUR. These waives are defined on the lists 
referred on the previous section (5).   
The content of PSUR should be in accordance with the template present on 
Annex II of Commission Implementing Regulation No. 520/2012. Guidance 
regarding on the information that should be inserted in each section is provided 
on GVP Module VII (29, 51). 
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I had the opportunity to participate in the preparation and submission of PSURs 
for Bluepharma’s products. In those submissions, requirements presented on 
EMA guidance document “National Competent Authorities and European 
Medicines Agency (EMA) requirements for submission of PSUR during the 
transitional period” were followed (53). Meanwhile, this guideline was 
suppressed by the following HMA guidance document: “Requirements on 
Submissions for Periodic safety update reports (PSUR) to National Competent 
Authorities for products authorised via National Procedures, Mutual Recognition 
Procedure and Decentralised Procedure”. At the time of the preparation of this 
report, no PSURs for Bluepharma’s products were submitted under these 
requirements (54). 
 
Taken into account the requirements presented on the supressed guidance, a 
CD-ROM with a .pdf version of the PSUR and a cover letter in paper were 
mailed to Portuguese competent authority.  
Being the active substance in cause subjected to Single Assessment, the 
guidance also requested the submission of the PSUR to all PRAC and CHMP 
members representing the national competent authorities of member-states 
where the medicinal products were authorised, to the PRAC rapporteur of the 
procedure, and to EMA. For this, as suggested in the guidance, we use the 
requirements present on the guidance document “Dossier requirements for 
Centrally Authorised Products”. Taken into account the requirements present in 
that guidance document, a PSUR is eCTD format was submitted to the above 
mentioned entities (55). This was the first time that a PSUR was by Bluepharma 
in this format, so it was a learning experience for all pharmacovigilance team. 
My tasks related to planning, preparation and submission of PSURs allowed me 
to get a greater knowledge about EEA legislation that regulates PSURs. By 
participating in the submission of PSURs in Europe I get the opportunity to 
observe how documents are submitted in eCTD format, which was a novelty for 
me. Before this experience I had no idea how many entities must be contacted 
for PSUR evaluation. Therefore, after this activity I realize that over time PSUR 
evaluation has the tendency to become more and more centralized process in 
EEA.  
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Mozambique 
As verified in the previous section for Portugal and the other EU member states, 
in Mozambique MAHs have the obligation to submit PSURs to competent 
authorities. This obligation is stated on Article 13 of Ministerial diploma No. 
53/2010. In accordance with this article, a MAH must submit a PSUR (56):  
 Immediately after authority’s solicitation, or; 
 Every six months in the first two years after MA approval, yearly in the 
next two years and every three years thereafter; 
 At renewal. 
 
In the following sections I will describe the activities that are related to PSUR 
planning, preparation and submission in Mozambique since the PSUR is 
forecasted to be submitted until it is submitted to Mozambican competent 
authorities. 
 
PSUR planning, preparation and submission 
Mozambican authorities provide MAHs with specific guidance regarding the 
production and submission of PSURs. MAHs can consult those 
recommendation on Ministerial diploma No. 53/2010 and on specific guidance 
documents. 
In order to have a better management of PSUR submission, the activities 
related to PSUR submission should be planned. This would allow me to obtain 
all the necessary documentation before its preparation. In Bluepharma I 
participated in the creation of an internal data-logger to manage PSUR 
submission to Mozambique. This data-logger was created based on Article 13 
of Ministerial Diploma No. 53/2010 submission requirements. Through this data-
logger it was possible a better tracking of PSURs to be submitted to 
Mozambican competent authority. Also, this data-logger allowed me to obtain 
data that can be used to evaluate the system regarding the submission of 
PSURs to Mozambique. 
 
Based on Mozambican guidance for the PSUR production provided to us by a 
local contact point, I participate also in the elaboration of an internal template for 
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the production of PSURs. In accordance with Mozambican guidelines a PSUR 
should contain the following structure (57): 
Cover Page 
1. Introduction 
2. Worldwide status 
3. Regulatory actions or actions taken by MAH due to safety reasons 
4. Updates of products reference information due to safety reasons 
5. Patient exposure 
6. ICSR history 
6.1 General considerations 
6.2 Presentation of listed cases 
6.4 Tabulated summaries 
6.5 ICSR analysis by MAH 
7. Studies 
7.1 Recently analysed studies by MAH 
7.2 New studies planned, initiated or on-going during PSUR preparation 
7.3Published safety studies 
8. Further information 
8.1 Efficacy-related information 
8.2 Late-breaking information 
8.3 Risk management 
8.4 Risk-benefit analysis 
9. General safety information 
10. Conclusion 
Annexes 
 
Based on the template created I had the chance to participate in the elaboration 
of several PSURs for all the products approved in Mozambique. After reviewed 
and signed by our EU-QPPV and our vice-president, PSURs were shipped to 
our local contact for a further revision. After reviewed, the local contact 
delivered PSURs to Mozambican authorities for evaluation. 
 
In conclusion, with the activities related to PSUR preparation and submission 
for Bluepharma’s products approved in Mozambique, I was able to acquire 
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knowledge about the pharmacovigilance requirements for other countries 
outside EEA. Another interesting finding for me was the fact that in comparison 
with EEA requirements, Mozambican requirements were very similar. This may 
due to the fact that both entities recognize CIOMS recommendations about 
PSURs. Additionally, with this activity I acquired experience related to system 
management. Through the data-logger, whose creation I was involved, it was 
possible to track all PSURs to be submitted and to periodically assess the 
system in order to improve it. 
 
2.2.7 Safety Variations 
The reference information of a medicinal product, in an European context, is 
restricted to the SmPC of the medicinal product. SmPC is, as present on EC 
guideline on SmPC, the basis of information for healthcare professional on how 
to use a medicinal use in a safely and effective manner. In other words, a 
SmPC is a regulatory document that contains the most up-to-date scientific 
information regarding the medicinal product (5, 58). 
The submission of a proposed SmPC upon a MAA is mandatory for all 
applicants. As stated on Article 10 of Directive 2001/83/EC, for generic 
medicines MAA the applicants are not obligate to provide the results of pre-
clinical and clinical studies. Therefore, the information to be inserted on the 
proposed SmPC will not result from studies performed by the applicant. Instead, 
this information should, with exception for information protected by patent, be in 
accordance with information present on the available innovative’s SmPC. 
In accordance with Article 11 of Directive 2001/83/EC, a SmPC, for medicinal 
products, has the following structure (5, 58): 
1. Name of the medicinal product 
2. Qualitative and quantitative composition. 
3. Pharmaceutical form. 
4. Clinical particulars: 
4.1. Therapeutic indications, 
4.2. Posology and method of administration, 
4.3. Contra-indications, 
4.4. Special warnings and precautions for use, 
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4.5. Interaction, 
4.6. Use during pregnancy and lactation, 
4.7. Effects on ability to drive and to use machines, 
4.8. Undesirable effects, 
4.9. Overdose  
5. Pharmacological properties: 
5.1. Pharmacodynamic properties, 
5.2. Pharmacokinetic properties, 
5.3. Preclinical safety data. 
6. Pharmaceutical particulars: 
6.1. List of excipients, 
6.2. Major incompatibilities, 
6.3. Shelf life, 
6.4. Special precautions for storage, 
6.5. Nature and contents of container, 
6.6. Special precautions for disposal. 
7. Marketing authorisation holder. 
8. Marketing authorisation number(s). 
9. Date of the first authorisation or renewal of the authorisation. 
10. Date of revision of the text. 
 
As presented on the list above, a SmPC contains several types of information: 
from administrative information, to quality propertied, and to efficacy and safety 
information. By obvious reasons, information contained in Section 4 (Clinical 
particulars) and Section 5 (Pharmacological properties) is the most susceptible 
to be affect by pharmacovigilance activities.  
Due to studies performed by the innovative product or by assessments of safety 
information performed by regulatory authorities, in particular PRAC, the 
information presented on those sections may need to be updated (5, 18). MAHs 
of generic medicines should be aware of those changes because it may be 
necessary the submission of variations to update the medicinal product 
information. 
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In the following sections I will describe how changes on innovatives’ reference 
information are detected and, when necessary, how Bluepharma’s products 
SmPC are updated using safety variations. 
 
Authorities’ recommendations 
As referred, generics reference information should be consistent with those 
presented by innovative product. Therefore, MAHs of generics should be aware 
of changes in innovative product information. In Bluepharma I had the 
opportunity to monitor the occurrence of those changes.  
When changes to references information occur, these have to be approved by 
Competent Authorities. EMA and HMA committees are responsible for providing 
recommendations for MAHs regarding new safety concerns. New safety 
recommendations may arise mostly by two procedures: evaluation of reference 
products PSURs or through signal detection. Within the weekly monitoring of 
changes in pharmacovigilance legislation, I had to monitor the changes in the 
safety information of innovative products of Bluepharma products. 
 
Recommendations from PSUR evaluation 
Depending on the approval procedure used by reference product, the institution 
that provides the outcomes of PSUR assessment will depend. In case of 
Centrally Authorised Products, PRAC and CHMP are responsible for releasing 
the outcomes of PSUR evaluation. In these cases a report following PSUR 
evaluation is performed by a rapporteur appointed by PRAC. After discussion 
during the monthly meeting a recommendation is published on PRAC minutes 
(51).  
A second stage involves the approval of these recommendations by CHMP. 
After CHMP monthly meeting, a document with the name Recommendation on 
safety variations is published by CHMP. In this document PRAC 
recommendations following PSUR evaluation are discussed and approved. 
After their publication MAHs have thirty days to apply the recommendations 
(51). 
In case of Nationally Authorized Products, CMDh release a document called 
Summary of PSUR Assessment Report where the outcomes of PSUR 
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evaluation are published. There is no legal obligation to implement the 
recommendations presented on Summary of PSUR Assessment Reports. 
However, it is suggested to implement the recommendations in ninety days 
after its publications (52). 
 
Figure 10 – PSUR assessment procedure for “EU single assessment” (51) 
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During pharmacovigilance legislation monitoring activities I had to take special 
attention to the publication of the outcomes of PSUR assessments applied to 
Bluepharma’s products by these authorities. When I detected a publication 
affecting a Bluepharma’s product, I had to assess how the information of the 
product was affected.  
 
PRAC recommendations on Safety Signals 
One of the tasks delegated to PRAC is the assessment of safety signals related 
to medicinal products with MA in EEA, independently the type of procedure (5, 
29, 59). A signal has been described as a possible new potential causal 
association between an intervention and the occurrence of an event (29, 59). 
Each month, the Agency publishes an overview listing all signals discussed 
during the latest PRAC meeting and the recommendations given for each of 
them. This is made by the publication of a document called PRAC 
recommendations on signals adopted at the PRAC meeting. MAHs are required 
to proactively monitor the publication of those documents, in order to keep 
product’s information up-to-date. The time for implementation is generally 
described with the recommendations (60). 
For innovative products approved by national procedures, national competent 
authorities are expected to provide translations of PRAC recommendations on 
safety signals. As presented on Infarmed’s Circular Informativa No. 
231/CD/8.1.6., Infarmed provides this service in its website. However, MAHs 
should use the recommendation’s publication date by PRAC for submission 
purposes (61). If innovative product is a Centrally Authorized Product, and after 
further contact with Infarmed, it is recommended to implement the variations 
after innovative product’s European Public Assessment Report had been 
updated. 
 
One the tasks delegated to me consisted in the monitoring of the publication of 
PRAC recommendations. After their publication I evaluated if any changes to 
Bluepharma’s products information occurred and if translations were already 
available at the time. If no translations were available I had to monitor their 
publication. 
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Other sources of safety variations 
Authorities may publish safety recommendations by several other means 
besides the above mentioned. Recommendations following referral procedures 
under several articles of Directive 2001/83/EC (such as Articles 30, 31 or 107) 
and updating product information following the evaluation of renewal 
applications, are other regulatory procedures used by regulatory agencies to 
recommend updates to product’s information.  
However, those procedures did not require my monitoring. Following the 
outcomes of those procedures, MAHs are recommended to submit a safety 
variation. When a recommendation is made, MAHs are directly contact by 
competent authorities through an official letter. Additionally, the variation 
classification and time available for recommendation implementation is also 
provided in the notification. 
 
Variation preparation and Submission 
Requirements for the submission of variation applications are defined on 
Commission Regulation No. 1234/2008 (62). Requirements regarding the 
classification of variations are presented on European Commission Guideline 
on variations (43). However, since not all variations are presented on this 
guideline, MAHs should also be taking into account the classification of 
variations present on the list CMDh Recommendation for classification of 
unforeseen variations according to Article 5 of Commission Regulation (EC) No 
1234/2008” when implementing safety variations (63). 
 
The preparation of a variation involves the following steps: 
1. Identification the need for variation; 
2. Internal variation codification; 
3. Updating product information; 
4. Preparation variation form. 
In Portugal, current legislation says that variations need to be submitted through 
Infarmed’s electronic plataform for variation submission SMUH-ALTER, as 
required by Commission Regulation (EC) No 1234/2008 (42, 62). This way, a 
variation should be submitted by creating a new variation application using 
  
University of Aveiro                                       Master in Pharmaceutical Medicine 
Page | 70  
 
company’s account in SMUH-ALTER. Following the variation application 
submission an e-mail alert with payment references is sent to Bluepharma. 
Infarmed will only start the evaluation process after the payment had been 
performed. 
During my internship in Bluepharma I had contact with activities related to the 
preparation and the submission of variations. I had the opportunity to fill 
variation forms used during variation application. Using SMUH-ALTER platform 
I made entries for variation applications for Bluepharma products. Following the 
reception of the e-mail alert with the payment references, I learned what the 
internal procedure to perform payments. Therefore, I was involved in all steps 
needed to successfully submit a variation. 
 
Variation application submission is a core activity in any regulatory affairs 
department. Within the scope of this activity I had the opportunity to prepare 
and submit variation applications. I understood that this is a very bureaucratic 
activity, since every changes proposed to product information had to be 
recorded in the application form. Also, I understood that special attention should 
be taken regarding previous approved or under evaluation variations with 
impact on product’s information. This should be made in order to avoid the loss 
of information when submitting the proposed texts.  
Another important learning that I acquired with this activity were the fee waivers 
for generic medicines. As happens in several other activities within 
pharmaceutical industry, MAHs of generic medicines have access to special 
waivers that allow them to pay reduced fees.  
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2.3 Regulatory Affairs activities 
 
Regulatory Affairs represents a set of regulatory activities that are performed by 
MAHs in order to submit and maintain medicinal products dossiers. Although 
this internship was focused on pharmacovigilance-related, I had the opportunity 
to be in contact with some activities related to regulatory affairs field. Some of 
this activities involved the interaction between pharmacovigilance sector and 
regulatory affairs members. Other were purely related to regulatory affairs, such 
as exportation-related activities. 
In the following section I start to describe the activities that involved 
coordination between pharmacovigilance sector and regulatory affairs 
members. On the second part of this section I will describe some exportation-
related activities in which I was involved. 
 
2.3.1 Regulatory Affairs and Pharmacovigilance 
During my internship I came across with some activities that, in their nature, 
involved the interaction between the pharmacovigilance sector and regulatory 
affairs department. These were the cases of safety variations, which required 
coordination for their internal codification and submission, and submission of 
RMPs during MAA, as referred on the respective sections of this report. 
 
Besides those activities, the coordination between regulatory affairs department 
and pharmacovigilance sector were also essential during the preparation and 
submission of renewal applications for Bluepharma’s products. 
In accordance with Article 27 of Decree-Law 176/2006, in Portugal a MA is valid 
for five years. After renewed for the first time the MA is valid indefinitely, unless 
otherwise specified by Infarmed. Article 28 states that renewal application 
should include a consolidated and updated report of product’s safety profile, 
including an evaluation of data from reports of suspected adverse reactions, 
and a description of product’s pharmacovigilance data (50). For that purpose, 
further guidance provided by Infarmed suggest MAHs to submit in sub-section 
2.5 of CTD an addendum to clinical overview accompanied by a clinical expert 
declaration (64, 65). 
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Guidance regarding this addendum is provided by HMA. In according to it, it 
should contain at least (66): 
 History of pharmacovigilance system inspections; 
 Worldwide marketing approval status; 
 Actions taken for safety reasons during the period covered since the 
initial marketing authorisation or since the last renewal; 
 Significant changes to the SmPC during the period covered since the 
initial marketing authorisation or since the last renewal; 
 Estimated exposure; 
 AE data in summary tabulations; 
 Summaries of significant safety and efficacy findings from clinical trials 
and non-interventional studies; 
 Relevant literature found in the period that might have impact benefit/risk 
of the medicinal product; 
 Benefit/risk balance; 
 Late breaking information; 
 Clinical expert declaration. 
During my internship I had the opportunity to be involved in the production of 
addendum to clinical overview to several Bluepharma’s products. Since the 
similarity between the information that should be included on these addendums 
and in a PSUR it is suggested to use as guidance GVP module VII in order to fill 
addendum’s sections. Therefore, by producing those addendums I had the 
opportunity to acquire more knowledge about the content of a PSUR and 
understand the relationship of PSURs and the addendums. 
 
In conclusion, by coming across with these activities I got the opportunity to 
observe the existing relations between pharmacovigilance sector and regulatory 
affairs department, due to their highly regulatory nature. I additionally learned 
how a renewal process is conducted and the information needed to successfully 
complete the process. 
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2.3.2 MAA preparation and submission for Mozambique 
The registry of medicinal products in Mozambique are regulated by 
Mozambican Decree No. 22/99 and by Law No. 4/98 (also referred as Medicinal 
Products Law). The medicinal products registered in this country are valid for 
five years and renewable in equal period (67). 
Two types of MAA are allowed in Mozambique: full application or abbreviate 
application. An abbreviate application does not require a tighter evaluation of 
quality, safety and efficacy documentation by authorities as a full application, 
and so it presents a shorter time for approval. However, this can only be done if 
the product intended for registration as already an MA on a country recognized 
by the Mozambican republic as a reference state and is being marketed. In 
accordance with Mozambican legislation, Portugal is considered a state of 
reference. (67).  
 
Exportation is one of Bluepharma’s business activities. Mozambique is one 
country where Bluepharma has MAs. During my activities related to exportation 
for Mozambique, I learned that Bluepharma’s applications for MAs in 
Mozambique are made using abbreviated applications. 
 
In accordance with Mozambican guidance, a MAA in Mozambique shall include 
a technical dossier with the following structure (67): 
 Part I – Administrative information and product characteristics; 
 Part II – Chemical and pharmaceutical documentation; 
 Part III – Safety documentation; 
 Part IV – Efficacy documentation. 
 
Besides the technical dossier, the application shall additionally contains the 
following documentation (67): 
 Certificate of a Pharmaceutical Product of the medicinal product; 
 Copy of MA in the reference state; 
 Copy of manufacturing authorization; 
 Copy of product’s SmPC and mock-ups in the country of origin. 
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After the dossier preparation, it was reviewed by Bluepharma’s submission 
manager for Mozambican applications. Accordingly with Article 17 of Decree 
No. 22/99 the application as to be delivered in person to Mozambican authority 
by the applicant (or its legal representative) (67). Therefore, after reviewed the 
dossiers were shipped product samples to Bluepharma’s local representative in 
Mozambique. After approval by Mozambican competent authorities, local 
contact sent to Bluepharma a scanned copy of the MA diploma. 
During my internship I had the opportunity to be involved in activities related to 
the preparation and submission of dossiers for MAA in Mozambique. 
 
Within the scope of this task, I had the opportunity to be involved in one of 
Bluepharma’s business pillars: exportation. By doing this I had the opportunity 
to get knowledge on Mozambican requirements for MAA and the different 
procedures in place that applicants can use when submitting a MAA. Since this 
activity involved the consultation of products’ dossiers, it also allowed me to 
obtain a greater knowledge on CTD content (especially on Quality section). 
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2.4 Cosmetics and Market Surveilance 
 
After several amendments to Council Directive No. 76/768/EEC of 27 July 1976 
regarding cometic products, at November 30 of 2009 it was published in the 
Official Journal of the European Union the Regulation (EC) No. 1223/2009. This 
Regulation replaced the Council Directive and thereof being the legal basis for 
the commercialization of cosmetic products in all EEA states (68). 
 
In order to establish an effective market surveillance system Regulation (EC) 
No. 1223/2009 provide to Responsible Person (i.e. a manufacturer established 
in EEA) and distributors clear rules about the recording and reporting of 
Undesirable Effects (i.e. adverse reaction attributable to the normal or 
reasonably foreseeable use of a cosmetic product). Those rules are presented 
on Article 23, which states that in the presence of serious undesirable effects 
(SUE), the responsible person and distributors shall without delay notify the CA. 
Further guidance on SUE management and reporting was provided by 
European Commission in 2012 on its SUE Reporting Guidelines. In accordance 
with these guidelines, SUE should be reported in no more than twenty calendar 
days since the Responsible Person, or the distributor, become aware of it. The 
report shall be accompanied by a causality assessment. In the event of SUE 
detected by the distributor, the guideline suggests that Responsible Person 
should provide assistance to distributor during causality assessment (69). 
 
Based on this regulation and on these guidelines, I participated in the 
production of an internal procedure in order to manage possible SUE related to 
cosmetic products distributed by Bluepharma. This task allowed me to 
understand the safety requirements for other sectors beyond medicinal 
products, namely those related to cosmetics. Since an internal template for 
procedures was used, it also allowed to obtain a better understand on the 
content of this type of document and obtain experience in its production. 
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2.5 Scientific Service activities 
 
In accordance with Article 156 of Decree-law No. 176/2006 (transposing Article 
98 of Directive 2001/83/EC), MAHs should have in place a scientific service in 
charge of information about the medicinal products which placed on the market. 
Scientific service is responsible to ensure that Bluepharma (50): 
 Communicate and provide a sample to competent authorities of all 
advertising activities related to Bluepharma products; 
 Keep records of advertising activities performed by the company; 
 Ensure that all advertising activities comply with the legal requirements; 
 Ensure the adequate training of pharmaceutical representatives; 
 Interaction with the authorities responsible for advertising of medicinal 
products in Portugal. 
During my internship, I took part in activities related to advertising and 
promotion of Bluepharma’s products to healthcare providers, within the scope of 
Bluepharma’s Scientific Service responsibilities. 
One of my major tasks related to Bluepharma’s scientific service was the 
update of the restricted area for healthcare professionals in Bluepharma’s 
website. When a new product is launched I had to update this area by creating 
an entry in website’s back-office with the following information: 
 Products name; 
 Presentations marketed; 
 Reimbursement level; 
 Annexes with product’s SmPC and BA/BE study results. 
 
As present on Article 164 of Decree-law No. 176/2006, the entity responsible for 
an advertising activity for a medicinal product has to provide a copy of it to 
Infarmed in ten calendar days (50).  Within this scope I had the opportunity to 
learn how MAHs notify Portuguese authorities when a new advertising activity is 
performed. I learned that MAHs shall use GPUB platform (see Figure 11) and 
the information needed to fulfill the notification. 
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Figure 11 – GPUB plartform 
 
Besides these activities I also take part on several other scientific service-
related activities, such as preparation of advertising pieces, information 
requests, sales representatives training and sponsoring activities (except 
sponsoring of clinical trials). 
 
This was a very enrichment experience for my professional growth. With the 
activities related to Bluepharma’s scientific service in which I was involved, I got 
the opportunity to complement my theoretical knowledge related to advertising 
of medicinal products acquired on relevant curricular units. I also learned how to 
use new tools related to authorities notification. Within the scope of notifications, 
I also understand the importance of communications between the people 
involved in the advertising of medicinal products. Since there are tight deadlines 
for notifications, it is almost mandatory to inform the scientific service 
immediately after an advertising piece is released into public. If the deadlines 
are not met Bluepharma may face monetary penalties. 
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3 DISCUSSION 
 
Before my internship in Bluepharma, my knowledge about the pharmaceutical 
industry was very limited, particularly in the generic medicines field. And 
ultimately my knowledge related to Bluepharma was even scarcer. 
At the begging of my internship in Bluepharma, I had obviously expectations 
that I was trying to accomplish and fears that I was hoping to successfully 
overcome. This was my first working experience and I was seeking the chance 
to apply the knowledge acquired in academia in real-world situations. 
Internal learning sessions that new collaborators are obligate to attend were 
very important for me to realize how Bluepharma is structured, how processes 
are conducted and what Bluepharma’s core activities are. In the activities that I 
was involved during my internship I got the opportunity to identify and 
understand some specificity of generic medicines that allowed the distinction 
from innovative medicines. 
With this internship I begin my professional life related to the regulatory field 
within the pharmaceutical industry. Before this internship my experience was 
confined to curricular units attended in academia. Therefore, before this 
internship I had high expectations since I would have the opportunity to obtain a 
better and broader knowledge in this field. However, I also feared that I would 
not have the right profile to conduct this type of activities, since it involves a lot 
of interaction with other persons. 
My activities, as referred throughout this report, were based on the regulatory 
field of pharmacovigilance, the regulatory field of pharmaceutical industry 
related to the safety of medicines. As referred in the previous sections there are 
a significant number of activities that are under pharmacovigilance scope, and 
although distinguishable from each other all of them are somewhat related to 
each other. Although not surprised by the fact, I also realized that there is not 
much space for innovation in the way how activities should be conducted, due 
to its highly regulatory basis. At the end of this internship, I realized that the 
activities developed in this field involve much more team work and are much 
more diversified than I expected at the beginning. However, there are still 
activities that shall be conducted in a more solitary manner. But, even in those 
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activities communication with other members is still needed to communicate the 
outcomes.  
During my internship I obtained a better knowledge about the legislation 
regulating the pharmaceutical industry. Although during academia experience I 
had contact with the rules governing this industry, the way how they are applied 
was a novelty for me. Due to the high number of regulatory documents it is 
essential to choose the right ones in order to comply with the right 
requirements. As I had the opportunity to observe when a submission does not 
comply with the requirements the competent authority may invalid the 
submission, which may lead to the loss of part of the fee paid and always to the 
loss of valuable time. Therefore, when conducting this type of activities special 
attention should be taken when interpreting what is stated in legislation and 
when case contact the authorities for further explanations. 
Pharmacovigilance legislation is in continuous mutation. Between 2010 and 
2012 main changes occurred in EU legislation. In academia I learned what 
changes this reform brought to pharmaceutical industry. However, only when I 
started to work in the field I realized how those changes affected MAHs 
activities. These activities had become much more harmonized, although the 
burden of activities increased exponentially. Since many of these changes are 
still being implemented, MAHs have to be aware of their implementation. In this 
way I understood how important is to a MAH to be aware of authorities’ 
publications in comparison with other regulatory activities with an older and 
stable legislation. 
Bluepharma is a growing company, and therefore new projects are continuously 
being created inside the company. Many of those projects required appropriate 
regulatory follow-up. Either to exportation projects requiring the assistance of 
pharmacovigilance sector either following the acquisition of a new MA for 
Bluepharma’s portfolio, those projects involved generally an increase in 
pharmacovigilance responsibilities. Since several projects were running at the 
same time it was easily to accumulate work. During my internship I realized that 
it was not possible to overrun all projects at the same time, being essential to 
prioritize the tasks that needed to be fulfilled. It should also be referred that this 
normally occurred in peaks, when new tasks accumulated with tasks normally 
developed by the department. 
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Another important learning acquired in this internship besides complying with 
dates is to perform tasks as pragmatic as possible. When performing a task the 
objective should be to comply with the requirements in the simplest way 
possible. This way, the task would be performed in a more efficient manner and 
avoid future delays, such as responses to deficiency letters from authorities.  
As described in the above sections, the fact that Bluepharma’s 
pharmacovigilance sector is located within the Regulatory Affairs department, it 
allowed me to obtain an experience not limited to pharmacovigilance field. I also 
had the opportunity to participate in several activities related to the MAA and 
MA management, besides the ones related to Bluepharma’s and scientific 
service. I believe this is an advantage for my future since I get a broader 
experience in regulatory field related to pharmaceuticals.  
Although I had felt some difficulties with new tasks allocated to me during this 
internship, due to their novelty to me, I surpassed them. For this mostly 
contributed the help provided by all department colleagues, the understanding 
of variables associated with the tasks and performing the same task for other 
products. 
At the end of this internship I believe that proposed objectives were 
accomplished. I was able to be in contact with legislation currently governing 
pharmaceutical industry activities and understand how it is applied, in particular 
the legislation related to pharmacovigilance. I had the opportunity to obtain a 
deeper knowledge on regulatory affairs field, since I had the opportunity to 
observe and understand what activities are normally developed in this field. I 
was also able to give a small contribute to the success of several Bluepharma’s 
projects. By attending and participating in several internal learning sessions I 
was able to understand what pharmaceutical industry is and that before a 
medicine is released into market several people had to participate in order to 
ensure its high quality standards. I also had the opportunity to participate in an 
internal project of learning sessions. This project was known as “Fórum da 
Inovação e Qualidade”. Within this project, in collaboration with the other 
members of pharmacovigilance team, I provided several training session related 
to pharmacovigilance to Bluepharma’s collaborators. This was a very rewarding 
experience for me because I had the chance to improve my presentation skills. 
Also, with this experience I understood the need for adapting my presentation to 
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the audience, since there were people with different levels of knowledge about 
pharmacovigilance. 
As final remark, this internship allowed me to understand and gain useful 
experience in regulatory affairs filed, the field that I want to build my 
professional life in the future. Through it I gained and enhanced several 
technical and interpersonal skills. A list of skills acquired is provided below. 
 
Technical skills 
 EEA regulatory framework of medicinal products 
 EEA regulatory framework of pharmacovigilance and scientific service 
activities 
 Medicinal Products and Cosmetics regulatory framework 
 Knowledge about the structure and content of several types of regulatory 
documentation (e.g. SmPC, Patient Information Leaflet…) 
 Knowledge on PSUR, RMP and other pharmacovigilance-related 
documentation structure and content 
 Knowledge on PSUR, RMP and other pharmacovigilance-related 
documentation preparation and submission 
 Medical and scientific literature monitoring 
 ICSR production and submission 
 Medicinal product dossier preparation and submission 
 Variation preparation and submission 
 Knowledge about CTD and eCTD structure and content 
 Pharmacovigilance system management 
 Advertising regulatory management of medicinal products 
 Preparation of specific regulatory documentation 
 
Soft skills 
 Team work 
 Work under pressure 
 Time management 
 Sense of organization 
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 Pragmatism when performing a task 
 Sense of responsibility 
 Autonomy 
 Attention to details 
 Critical judgment 
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4 CONCLUSION 
 
Pharmacovigilance science arose from dark moments of the pharmaceutical 
sector with the need to develop medicinal products with high levels of safety. 
Pharmacovigilance science is an every changing science that tries to adapt to 
the most up-to-date scientific and technological discoveries. Current tools are 
the result of more than fifty years of developments in the field. 
Pharmacovigilance activities are mainly regulatory-based, this is they have to 
be made in order to comply with requirements provided by regulatory 
authorities. During this internship, I observed the application of the latest 
revolution in pharmacovigilance derived from the publication of 2010 and 2012 
new pharmacovigilance legislation. This new legislation framework created new 
responsibilities that MAHs had to comply. Although this new legislation allowed 
an harmonized way how several activities are done within EEA, this new 
legislation had also forced MAHs to increase the allocation of resources (both 
human and financial) to the pharmacovigilance activities in order to comply with 
them. 
During my internship I had the opportunity to participate in several 
pharmacovigilance-related activities. Most of these activities were related to 
each other. Therefore, coordination and communication between 
pharmacovigilance sector members is essential.  
Due to its regulatory specificity, in Bluepharma pharmacovigilance sector is 
associated with Regulatory Affairs department. This allowed me to gain 
knowledge in several other activities related to application and maintenance of 
MAs.  
This internship also allowed me to apply concepts discussed on academic 
phase. This is an advantage for me since it allowed me to obtain a better 
understanding of them and why they are applied. 
In conclusion, this internship allowed me to get my first working experience. 
With it I got a better and broader understanding of several concepts already 
discussed in the academic setting and to understand the application of several 
others. Being involved in a team, this internship allowed me to develop several 
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interpersonal skills. Finally, this internship allowed me to develop several skills 
essential for my future in the regulatory field of the pharmaceutical industry. 
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